#BEGIN_DRUGCARD DB00172

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Hepatic

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
147-85-3

# ChEBI_ID:
17203

# Chemical_Formula:
C5H9NO2

# Chemical_IUPAC_Name:
(2S)-pyrrolidine-2-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
A non-essential amino acid that is synthesized from glutamic acid. It is an essential component of collagen and is important for proper functioning of joints and tendons. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Dietary supplement
Micronutrient
Non-Essential Amino Acids

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Nutraceutical
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-2.54

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
1.62E+005 mg/L (at 25 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
L-Proline

# HET_ID:
PRO

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C5H9NO2/c7-5(8)4-2-1-3-6-4/h4,6H,1-3H2,(H,7,8)/t4-/m0/s1

# InChI_Key:
InChIKey=ONIBWKKTOPOVIA-BYPYZUCNSA-N

# Indication:
L-Proline is extremely important for the proper functioning of joints and tendons and also helps maintain and strengthen heart muscles.

# KEGG_Compound_ID:
C00148

# KEGG_Drug_ID:
D00035

# LIMS_Drug_ID:
172

# Mechanism_Of_Action:
Glycogenic, by L-Proline oxidase in the kidney, it is ring-opened and is oxidized to form L-Glutamic acid. L-Ornithine and L-Glutamic acid are converted to L-Proline via L-Glutamic acid-gamma-semialdehyde. It is contained abundantly in collagen, and is intimately involved in the function of arthrosis and chordae.

# Melting_Point:
221 dec °C

# Molecular_Weight_Avg:
115.1305

# Molecular_Weight_Mono:
115.063328537

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
1H4T

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA451125

# Pharmacology:
L-Proline is a major amino acid found in cartilage and is important for maintaining youthful skin as well as repair of muscle, connective tissue and skin damage. It is also essential for the immune system, and for necessary balance of this formula. It is an essential component of collagen and is important for proper functioning of joints and tendons. L-Proline is extremely important for the proper functioning of joints and tendons. Helps maintain and strengthen heart muscles.

# Predicted_LogP_Hydrophobicity:
-2.7

# Predicted_LogS:
0.5

# Predicted_Water_Solubility:
3.65e+02 g/l

# Primary_Accession_No:
DB00172

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
145742

# PubChem_Substance_ID:
46506858

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
NUTR00047

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC(=O)[C@@H]1CCCN1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
(-)-2-Pyrrolidinecarboxylic acid
(-)-Proline
(S)-2-Carboxypyrrolidine
(S)-2-Pyrrolidinecarboxylic acid
(S)-Proline
2-Pyrrolidinecarboxylic acid

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:09 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/L-Proline

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
PRODH

# Phase_1_Metabolizing_Enzyme_1_ID:
4082

# Phase_1_Metabolizing_Enzyme_1_Name:
Proline oxidase, mitochondrial

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Proline oxidase, mitochondrial
MLEFVMREWKKSRKLLGQRLFNKLMKMTFYGHFVAGEDQESIQPLLRHYRAFGVSAILDY
GVEEDLSPEEAEHKEMESCTSAAERDGSGTNKRDKQYQAHRAFGDRRNGVISARTYFYAN
EAKCDSHMETFLRCIEASGRVSDDGFIAIKLTALGRPQFLLQFSEVLAKWRCFFHQMAVE
QGQAGLAAMDTKLEVAVLQESVAKLGIASRAEIEDWFTAETLGVSGTMDLLDWSSLIDSR
TKLSKHLVVPNAQTGQLEPLLSRFTEEEELQMTRMLQRMDVLAKKATEMGVRLMVDAEQT
YFQPAISRLTLEMQRKFNVEKPLIFNTYQCYLKDAYDNVTLDVELARREGWCFGAKLVRG
AYLAQERARAAEIGYEDPINPTYEATNAMYHRCLDYVLEELKHNAKAKVMVASHNEDTVR
FALRRMEELGLHPADHQVYFGQLLGMCDQISFPLGQAGYPVYKYVPYGPVMEVLPYLSRR
ALENSSLMKGTHRERQLLWLELLRRLRTGNLFHRPA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
O43272

# Drug_Target_10_Cellular_Location:
Nucleus

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
PPIG

# Drug_Target_10_GenBank_ID_Gene:
U40763

# Drug_Target_10_GenBank_ID_Protein:
1117968

# Drug_Target_10_GeneCard_ID:
PPIG

# Drug_Target_10_Gene_Name:
PPIG

# Drug_Target_10_Gene_Sequence:
>2265 bp
ATGGGAATAAAGGTTCAACGTCCTCGATGTTTTTTTGACATTGCCATTAACAATCAACCT
GCTGGAAGAGTTGTCTTTGAATTATTTTCTGATGTGTGCCCCAAAACATGCGAGAACTTT
CGTTGTCTTTGTACAGGTGAAAAGGGGACCGGGAAATCAACTCAGAAACCATTACATTAT
AAGAGTTGTCTCTTTCACAGAGTTGTCAAGGATTTTATGGTTCAAGGTGGTGACTTCAGT
GAAGGAAATGGACGAGGAGGGGAATCTATCTATGGAGGATTTTTTGAAGACGAGAGTTTC
GCTGTTAAACACAACAAAGAATTTCTCTTGTCAATGGCCAACAGAGGGAAGGATACAAAT
GGTTCACAGTTCTTCATAACAACGAAACCAACTCCTCATTTAGATGGGCATCATGTTGTT
TTTGGACAAGTAATCTCTGGTCAAGAAGTTGTAAGAGAGATTGAAAACCAGAAAACAGAT
GCAGCTAGCAAACCGTTTGCGGAGGTACGGATACTCAGTTGTGGAGAGCTGATTCCCAAA
TCTAAAGTTAAGAAAGAAGAAAAGAAAAGGCATAAATCATCATCATCTTCCTCCTCCTCA
TCTAGTGACTCAGATAGCTCAAGTGATTCTCAGTCCTCTTCTGATTCCTCTGATTCCGAA
AGTGCTACTGAAGAGAAATCAAAGAAAAGAAAAAAGAAACATCGGAAAAATTCCCGAAAA
CACAAGAAAGAAAAGAAAAAGCGAAAGAAAAGCAAGAAGAGTGCATCTAGTGAGAGTGAA
GCTGAAAATCTTGAAGCACAACCCCAGTCTACTGTCCGTCCAGAAGAGATCCCTCCTATA
CCTGAAAATAGATTCCTAATGAGAAAAAGTCCTCCTAAAGCTGATGAGAAGGAAAGGAAA
AACAGAGAGAGAGAAAGGGAAAGAGAGTGTAATCCACCTAACTCCCAGCCTGCTTCATAC
CAGAGACGACTTTTAGTTACTAGATCTGGCAGGAAAATTAAAGGAAGAGGACCAAGGCGT
TATCGAACTCCTTCCAGATCCAGATCAAGGGATCGTTTCAGACGTAGTGAGACTCCTCCA
CATTGGAGGCAAGAGATGCAGAGAGCTCAAAGAATGAGGGTATCAAGTGGTGAAAGATGG
ATCAAGGGGGATAAGAGTGAGTTGAATGAAATAAAAGAAAATCAGAGAAGTCCAGTTAGA
GTAAAAGAGAGAAAAATAACAGATCACAGGAATGTATCTGAGAGTCCAAACAGAAAAAAT
GAAAAGGAGAAGAAAGTTAAAGACCATAAATCTAACAGCAAAGAGAGAGACATCAGAAGA
AATTCAGAAAAAGATGACAAGTATAAAAACAAAGTGAAGAAAAGGGCCAAATCTAAAAGT
AGGAGTAAGAGCAAAGAGAAATCAAAGAGTAAAGAAAGAGATTCAAAACATAATAGAAAT
GAAGAAAAGAGGATGAGGTCAAGGAGTAAAGGAAGGGATCATGAAAATGTTAAAGAAAAA
GAAAAGCAGTCTGATTCTAAAGGAAAAGATCAGGAAAGGAGTAGAAGTAAAGAGAAGTCT
AAACAGTTAGAATCAAAGAGTAATGAGCATGATCACAGTAAAAGTAAGGAAAAGGATAGA
CGCGCACAATCCAGGAGTAGAGAATGTGATATAACTAAAGGTAAACACAGTTATAATAGC
AGAACAAGAGAACGAAGCAGAAGTAGGGACAGAAGCAGAAGAGTGCGATCAAGAACCCAT
GACAGAGATCGCAGCAGAAGCAAGGAGTACCATAGATACAGAGAACAGGAATACAGGAGA
AGAGGACGGTCACGAAGCCGAGAGAGAAGAACACCACCAGGAAGATCAAGAAGTAAAGAT
AGGAGGAGAAGGAGGAGAGACTCACGGAGCTCAGAGAGAGAAGAAAGTCAAAGCAGAAAC
AAAGACAAATACAGAAACCAAGAGAGTAAGAGCTCACACAGAAAAGAAAATTCTGAGAGT
GAGAAAAGAATGTACTCTAAAAGTCGTGATCATAATAGCTCAAATAACAGCAGGGAAAAA
AAGGCTGATAGAGATCAAAGTCCCTTCTCAAAAATAAAACAAAGCAGTCAGGACGATGAA
TTAAAGTCCTCCATGTTGAAAAATAAGGAGGATGAGAAGATCAGATCCTCAGTGGAAAAA
GAAAACCAAAAATCAAAAGGTCAAGAAAATGACCATGTACATGAAAAAAATAAAAAATTT
GATCATGAATCAAGCCCTGGAACAGATGAAGACAAGAGCGGATGA

# Drug_Target_10_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_10_General_References:
8973360	Nestel FP, Colwill K, Harper S, Pawson T, Anderson SK: RS cyclophilins: identification of an NK-TR1-related cyclophilin. Gene. 1996 Nov 21;180(1-2):151-5.
9153302	Bourquin JP, Stagljar I, Meier P, Moosmann P, Silke J, Baechi T, Georgiev O, Schaffner W: A serine/arginine-rich nuclear matrix cyclophilin interacts with the C-terminal domain of RNA polymerase II. Nucleic Acids Res. 1997 Jun 1;25(11):2055-61.

# Drug_Target_10_HGNC_ID:
HGNC:14650

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
4086

# Drug_Target_10_Locus:
2q31.1

# Drug_Target_10_Molecular_Weight:
88619

# Drug_Target_10_Name:
Peptidyl-prolyl cis-trans isomerase G

# Drug_Target_10_Number_of_Residues:
754

# Drug_Target_10_PDB_ID:
Not Available

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
PF00160	Pro_isomerase

# Drug_Target_10_Protein_Sequence:
>Peptidyl-prolyl cis-trans isomerase G
MGIKVQRPRCFFDIAINNQPAGRVVFELFSDVCPKTCENFRCLCTGEKGTGKSTQKPLHY
KSCLFHRVVKDFMVQGGDFSEGNGRGGESIYGGFFEDESFAVKHNKEFLLSMANRGKDTN
GSQFFITTKPTPHLDGHHVVFGQVISGQEVVREIENQKTDAASKPFAEVRILSCGELIPK
SKVKKEEKKRHKSSSSSSSSSSDSDSSSDSQSSSDSSDSESATEEKSKKRKKKHRKNSRK
HKKEKKKRKKSKKSASSESEAENLEAQPQSTVRPEEIPPIPENRFLMRKSPPKADEKERK
NRERERERECNPPNSQPASYQRRLLVTRSGRKIKGRGPRRYRTPSRSRSRDRFRRSETPP
HWRQEMQRAQRMRVSSGERWIKGDKSELNEIKENQRSPVRVKERKITDHRNVSESPNRKN
EKEKKVKDHKSNSKERDIRRNSEKDDKYKNKVKKRAKSKSRSKSKEKSKSKERDSKHNRN
EEKRMRSRSKGRDHENVKEKEKQSDSKGKDQERSRSKEKSKQLESKSNEHDHSKSKEKDR
RAQSRSRECDITKGKHSYNSRTRERSRSRDRSRRVRSRTHDRDRSRSKEYHRYREQEYRR
RGRSRSRERRTPPGRSRSKDRRRRRRDSRSSEREESQSRNKDKYRNQESKSSHRKENSES
EKRMYSKSRDHNSSNNSREKKADRDQSPFSKIKQSSQDDELKSSMLKNKEDEKIRSSVEK
ENQKSKGQENDHVHEKNKKFDHESSPGTDEDKSG

# Drug_Target_10_Reaction:
peptidylproline (omega=180) = peptidylproline (omega=0)

# Drug_Target_10_Signals:
None

# Drug_Target_10_Specific_Function:
PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. May be implicated in the folding, transport, and assembly of proteins. May play an important role in the regulation of pre-mRNA splicing

# Drug_Target_10_SwissProt_ID:
Q13427

# Drug_Target_10_SwissProt_Name:
PPIG_HUMAN

# Drug_Target_10_Synonyms:
CARS-Cyp
CARS-cyclophilin
CASP10
Clk-associating RS-cyclophilin
Cyclophilin G
EC 5.2.1.8
PPIase G
Peptidyl-prolyl isomerase G
Rotamase G
SR-cyclophilin
SR-cyp
SRcyp

# Drug_Target_10_Theoretical_pI:
11.00

# Drug_Target_10_Transmembrane_Regions:
None

# Drug_Target_11_Cellular_Location:
Endoplasmic reticulum

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
LEPRE1

# Drug_Target_11_GenBank_ID_Gene:
AF097431

# Drug_Target_11_GenBank_ID_Protein:
11127636

# Drug_Target_11_GeneCard_ID:
LEPRE1

# Drug_Target_11_Gene_Name:
LEPRE1

# Drug_Target_11_Gene_Sequence:
>2211 bp
ATGGCGGTACGCGCGTTGAAGCTGCTGACCACACTGCTGGCTGTCGTGGCCGCTGCCTCC
CAAGCCGAGGTCGAGTCCGAGGCAGGATGGGGCATGGTGACGCCTGATCTGCTCTTCGCC
GAGGGGACCGCAGCCTACGCGCGCGGGGACTGGCCCGGGGTGGTCCTGAGCATGGAACGG
GCGCTGCGCTCCCGGGCAGCCCTCCGCGCCCTTCGCCTGCGCTGCCGCACCCAGTGTGCC
GCCGACTTCCCGTGGGAGCTGGACCCCGACTGGTCCCCCAGCCCGGCCCAGGCCTCGGGC
GCCGGCGCCCTGCGCGACCTGAGCTTCTTCGGGGGCCTTCTGCGTCGCGCTGCCTGCCTG
CGCCGCTGCCTCGGGCCGCCGGCCGCCCACTCGCTCAGCGAAGAGATGGAGCTGGAGTTC
CGCAAGCGGAGCCCCTACAACTACCTGCAGGTCGCCTACTTCAAGATCAACAAGTTGGAG
AAAGCTGTTGCTGCAGCACACACCTTCTTCGTGGGCAATCCTGAGCACATGGAAATGCAG
CAGAACCTAGACTATTACCAAACCATGTCTGGAGTGAAGGAGGCCGACTTCAAGGATCTT
GAGACTCAACCCCATATGCAAGAATTTCGACTGGGAGTGCGACTCTACTCAGAGGAACAG
CCACAGGAAGCTGTGCCCCACCTAGAGGCGGCGCTGCAAGAATACTTTGTGGCCTATGAG
GAGTGCCGTGCCCTCTGCGAAGGGCCCTATGACTACGATGGCTACAACTACCTTGAGTAC
AACGCTGACCTCTTCCAGGCCATCACAGATCATTACATCCAGGTCCTCAACTGTAAGCAG
AACTGTGTCACGGAGCTTGCTTCCCACCCAAGTCGAGAGAAGCCCTTTGAAGACTTCCTC
CCATCGCATTATAATTATCTGCAGTTTGCCTACTATAACATTGGGAATTATACACAAGCT
GGTGAATGTGCCAAGACCTATCTTCTCTTCTTCCCCAATGACGAGGTGATGAACCAAAAT
TTGGCCTATTATGCAGCTATGCTTGGAGAAGAACACACCAGATCCATCGGCCCCCGTGAG
AGTGCCAAGGAGTACCGACAGCGAAGCCTACTGGAAAAAGAACTGCTTTTCTTCGCTTAT
GATGTTTTTGGAATTCCCTTTGTGGATCCGGATTCATGGACTCCAGAAGAAGTGATTCCC
AAGAGATTGCAAGAGAAACAGAAGTCAGAACGGGAAACAGCCGTACGCATCTCCCAGGAG
ATTGGGAACCTTATGAAGGAAATCGAGACCCTTGTGGAAGAGAAGACCAAGGAGTCACTG
GATGTGAGCAGACTGACCCGGGAAGGTGGCCCCCTGCTGTATGAAGGCATCAGTCTCACC
ATGAACTCCAAACTCCTGAATGGTTACCAGCGGGTGGTGATGGACGGCGTAATCTCTGAC
CACGAGTGTCAGGAGCTGCAGAGACTGACCAATGTGGCAGCAACCTCAGGAGATGGCTAC
CGGGGTCAGACCTCCCCACATACTCCCAATGAAAAGTTCTATGGTGTCACTGTCTTCAAA
GCCCTCAAGCTGGGGCAAGAAGGCAAAGTTCCTCTGCAGAGTGCCCACCTGTACTACAAC
GTGACGGAGAAAGTGCGGCGCATCATGGAGTCCTACTTCCGCCTGGATACGCCCCTCTAC
TTTTCCTACTCTCATCTGGTGTGCCGCACTGCCATCGAAGAGGTCCAGGCAGAGAGGAAG
GATGATAGTCATCCAGTCCACGTGGACAACTGCATCCTGAATGCCGAGACCCTCGTGTGT
GTCAAAGAGCCCCCAGCCTACACCTTCCGCGACTACAGCGCCATCCTTTACCTAAATGGG
GACTTCGATGGCGGAAACTTTTATTTCACTGAACTGGATGCCAAGACCGTGACGGCAGAG
GTGCAGCCTCAGTGTGGAAGAGCCGTGGGATTCTCTTCAGGCACTGAAAACCCACATGGA
GTGAAGGCTGTCACCAGGGGGCAGCGCTGTGCCATCGCCCTGTGGTTCACCCTGGACCCT
CGACACAGCGAGCGGGACAGGGTGCAGGCAGATGACCTGGTGAAGATGCTCTTCAGCCCA
GAAGAGATGGACCTCTCCCAGGAGCAGCCCCTGGATGCCCAGCAGGGCCCCCCCGAACCT
GCACAAGAGTCTCTCTCAGGCAGTGAATCGAAGCCCAAGGATGAGCTATGA

# Drug_Target_11_General_Function:
Not Available

# Drug_Target_11_General_References:
10951563	Kaul SC, Sugihara T, Yoshida A, Nomura H, Wadhwa R: Gros1, a potential growth suppressor on chromosome 1: its identity to basement membrane-associated proteoglycan, leprecan. Oncogene. 2000 Jul 27;19(32):3576-83.

# Drug_Target_11_HGNC_ID:
HGNC:19316

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
3945

# Drug_Target_11_Locus:
1p34.1

# Drug_Target_11_Molecular_Weight:
83395

# Drug_Target_11_Name:
Prolyl 3-hydroxylase 1

# Drug_Target_11_Number_of_Residues:
736

# Drug_Target_11_PDB_ID:
Not Available

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF03171	2OG-FeII_Oxy

# Drug_Target_11_Protein_Sequence:
>Prolyl 3-hydroxylase 1
MAVRALKLLTTLLAVVAAASQAEVESEAGWGMVTPDLLFAEGTAAYARGDWPGVVLSMER
ALRSRAALRALRLRCRTQCAADFPWELDPDWSPSPAQASGAAALRDLSFFGGLLRRAACL
RRCLGPPAAHSLSEEMELEFRKRSPYNYLQVAYFKINKLEKAVAAAHTFFVGNPEHMEMQ
QNLDYYQTMSGVKEADFKDLETQPHMQEFRLGVRLYSEEQPQEAVPHLEAALQEYFVAYE
ECRALCEGPYDYDGYNYLEYNADLFQAITDHYIQVLNCKQNCVTELASHPSREKPFEDFL
PSHYNYLQFAYYNIGNYTQAVECAKTYLLFFPNDEVMNQNLAYYAAMLGEEHTRSIGPRE
SAKEYRQRSLLEKELLFFAYDVFGIPFVDPDSWTPEEVIPKRLQEKQKSERETAVRISQE
IGNLMKEIETLVEEKTKESLDVSRLTREGGPLLYEGISLTMNSKLLNGSQRVVMDGVISD
HECQELQRLTNVAATSGDGYRGQTSPHTPNEKFYGVTVFKALKLGQEGKVPLQSAHLYYN
VTEKVRRIMESYFRLDTPLYFSYSHLVCRTAIEEVQAERKDDSHPVHVDNCILNAETLVC
VKEPPAYTFRDYSAILYLNGDFDGGNFYFTELDAKTVTAEVQPQCGRAVGFSSGTENPHG
VKAVTRGQRCAIALWFTLDPRHSERDRVQADDLVKMLFSPEEMDLSQEQPLDAQQGPPEP
AQESLSGSESKPKDEL

# Drug_Target_11_Reaction:
procollagen L-proline + 2-oxoglutarate + O2 = procollagen trans-3-hydroxy-L-proline + succinate + CO2

# Drug_Target_11_Signals:
1-22

# Drug_Target_11_Specific_Function:
Basement membrane-associated chondroitin sulfate proteoglycan (CSPG). Has prolyl 3-hydroxylase activity catalyzing the posttranslational formation of 3-hydroxyproline in -Xaa-Pro- Gly- sequences in collagens, especially types IV and V. May be involved in the secretory pathway of cells. Has growth suppressive activity in fibroblasts

# Drug_Target_11_SwissProt_ID:
Q32P28

# Drug_Target_11_SwissProt_Name:
P3H1_HUMAN

# Drug_Target_11_Synonyms:
EC 1.14.11.7
Growth suppressor 1
Leprecan-1
Leucine- and proline- enriched proteoglycan 1
Prolyl 3-hydroxylase 1 precursor

# Drug_Target_11_Theoretical_pI:
4.79

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Not Available

# Drug_Target_12_Chromosome_Location:
Not Available

# Drug_Target_12_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
P5CR2

# Drug_Target_12_GenBank_ID_Gene:
AF151351

# Drug_Target_12_GenBank_ID_Protein:
4960118

# Drug_Target_12_GeneCard_ID:
P5CR2

# Drug_Target_12_Gene_Name:
P5CR2

# Drug_Target_12_Gene_Sequence:
>960 bp
ATGAGCGTGGGCTTCATCGGGGCCGGCCAGCTGGCTATGCTCTGGCGCGGGGCTTCACGG
CCGCAGATTCCTGTCGGCTCACAAGATAATAGCCAGCTCCCCAGAAATGAACCTGCCCAC
GGTGTCCGCGCTCAGGAAGATGGGTGTGAACCTGACACGCAGCAACAAGGAGACGGTGAA
GCACAGCGACGTCCTGTTTCTGGCTGTGAAGCACATATCATCCCCTTCATCCTGGTTGAG
ATTGGGGCCGACGTGCAAGCCAGACACATCGTGGTCTCCTGTGCGGCTGGTGTTACCATC
AGCTCTGTGGAGAAGAAGCTGATGGAATTCCAGCCAGCCCCCAAAGTGATTCGCTGCATG
ACCAACACACCTGTGGTAGTGCAGGAAGGCGCTACAGTGTACGCCACGGGCACCCATGCC
CTGGTGGAGGATGGGCAGCTCCTGGAGCAGCTCATGAGCAGCGTGGGCTTCTGCACTGAG
GTGGAAGAGGACCTCATCGATGCCGTCACGGGGCTCAGTGGCAGCAAACCTGCCTATGCA
TTCATGGCTCTGGACGCATTGGCTGATGGTGGGGTGAAGATGGGTTTGCCACGGCGCCTG
GCAATCCAACTCGGGGCCCAGGCTTTGCTGGGAGCTGCCAAGATGCTGCTGGACTCGGAG
CAGCATCCATGCCAGCTTAAGGACAATGTCTGCTCCCCTGGGGGAGCCACCATCCACGCC
CTGCACTTTCTAGAGAGTGGGGGCTTCCGCTCTCTGCTCATCAATGCAGTTGAGGCCTCC
TGTATCCGAACACGAGAGCTACAGTCCATGGCCGACCAAGAAAAGATCTCCCCAGCTGCC
CTTAAGAAGACCCTCTTAGACAGAGTGAAGCTGGAATCCCCCACAGTCTCCACACTGACC
CCCTCCAGCCCAGGGAAGCTCCTCACAAGAAGCCTGGCCCTGGGAGGCAAGAAGGACTAA

# Drug_Target_12_General_Function:
Amino acid transport and metabolism

# Drug_Target_12_General_References:
Not Available

# Drug_Target_12_HGNC_ID:
HGNC:30262

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
4087

# Drug_Target_12_Locus:
Not Available

# Drug_Target_12_Molecular_Weight:
33727

# Drug_Target_12_Name:
Pyrroline 5-carboxylate reductase isoform

# Drug_Target_12_Number_of_Residues:
319

# Drug_Target_12_PDB_ID:
Not Available

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF03807	F420_oxidored

# Drug_Target_12_Protein_Sequence:
>Pyrroline 5-carboxylate reductase isoform
MSVGFIGAGQLAMLWRGASRPQIPVGSQDNSQLPRNEPAHGVRAQEDGCEPDTQQQGDGE
AQRRPVSGCEAHIIPFILVEIGADVQARHIVVSCAAGVTISSVEKKLMEFQPAPKVIRCM
TNTPVVVQEGATVYATGTHALVEDGQLLEQLMSSVGFCTEVEEDLIDAVTGLSGSKPAYA
FMALDALADGGVKMGLPRRLAIQLGAQALLGAAKMLLDSEQHPCQLKDNVCSPGGATIHA
LHFLESGGFRSLLINAVEASCIRTRELQSMADQEKISPAALKKTLLDRVKLESPTVSTLT
PSSPGKLLTRSLALGGKKD

# Drug_Target_12_Reaction:
Not Available

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
Not Available

# Drug_Target_12_SwissProt_ID:
Q4W8W1

# Drug_Target_12_SwissProt_Name:
Q4W8W1_HUMAN

# Drug_Target_12_Synonyms:
Not Available

# Drug_Target_12_Theoretical_pI:
5.91

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Mitochondrion

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
PARS2

# Drug_Target_13_GenBank_ID_Gene:
BC007956

# Drug_Target_13_GenBank_ID_Protein:
39644604

# Drug_Target_13_GeneCard_ID:
PARS2

# Drug_Target_13_Gene_Name:
PARS2

# Drug_Target_13_Gene_Sequence:
>1428 bp
ATGGAAGGGCTGCTGACAAGATGCAGAGCATTGCCCGCCCTGGCCACCTGCAGCCGCCAG
CTCTCTGGGTATGTTCCTTGCAGGTTTCACCACTGTGCCCCAAGAAGAGGGCGGCGCCTG
CTGCTGTCTCGTGTGTTCCAGCCACAGAACCTTCGGGAAGACCGGGTGCTCTCCCTGCAG
GACAAATCTGATGACCTGACCTGTAAGAGCCAGCGGCTGATGCTGCAGGTGGGCCTGATC
TACCCAGCAAGCCCCGGCTGTTACCACCTCCTGCCATATACCGTCCGTGCCATGGAGAAG
CTCGTGCGAGTGATAGACCAGGAGATGCAGGCCATCGGGGGCCAGAAAGTCAACATGCCC
AGCCTCAGCCCGGCAGAGCTCTGGCAAGCCACCAACCGGTGGGACTTGATGGGCAAAGAG
CTGCTAAGACTTAGAGACAGGCATGGCAAGGAATACTGCTTAGGACCAACTCACGAGGAA
GCCATTACGGCCTTAATTGCCTCCCAGAAGAAACTGTCCTACAAGCAGCTTCCCTTCCTG
CTGTACCAAGTGACAAGGAAGTTTCGGGATGAGCCCAGGCCCCGCTTTGGTCTTCTCCGT
GGCCGAGAGTTTTACATGAAGGATATGTACACCTTTGACTCCTCCCCAGAGGCTGCCCAG
CAGACCTACAGCCTGGTGTGTGATGCCTACTGCAGCCTGTTCAACAAGCTAGGGCTGCCA
TTTGTCAAGGTCCAGGCCGATGTGGGCACCATCGGGGGCACAGTGTCTCATGAGTTCCAG
CTCCCAGTGGATATTGGAGAGGACCGGCTTGCCATCTGTCCCCGCTGCAGCTTCTCAGCC
AACATGGAGACACTAGACTTGTCACAAATGAACTGCCCTGCTTGCCAGGGCCCATTGACT
AAAACCAAAGGCATTGAGGTGGGGCACACATTTTACCTGGGTACCAAGTACTCATCCATT
TTCAATGCCCAGTTTACCAATGTCTGTGGCAAACCAACCCTGGCTGAAATGGGGTGCTAT
GGCTTGGGTGTGACACGGATCTTGGCTGCTGCCATTGAAGTCCTCTCTACAGAAGACTGT
GTCCGCTGGCCCAGCCTACTGGCCCCTTACCAAGCCTGCCTCATCCCCCCTAAGAAGGGC
AGTAAGGAGCAGGCGGCCTCCGAGCTCATAGGGCAGCTGTACGACCACATCACAGAGGCA
GTGCCTCAGCTTCACGGGGAGGTGCTCCTGGACGACAGGACCCATCTGACCATCGGAAAC
AGACTGAAAGATGCCAACAAGTTTGGCTACCCCTTTGTGATAATCGCTGGCAAGAGGGCC
CTGGAGGACCCTGCACATTTTGAGGTTTGGTGTCAGAACACTGGTGAGGTGGCCTTCCTC
ACCAAAGATGGAGTCATGGATTTACTGACCCCAGTGCAGACTGTCTAA

# Drug_Target_13_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_13_General_References:
Not Available

# Drug_Target_13_HGNC_ID:
HGNC:30563

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
4088

# Drug_Target_13_Locus:
1p32.2

# Drug_Target_13_Molecular_Weight:
53263

# Drug_Target_13_Name:
Probable prolyl-tRNA synthetase, mitochondrial

# Drug_Target_13_Number_of_Residues:
475

# Drug_Target_13_PDB_ID:
Not Available

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00587	tRNA-synt_2b
PF03129	HGTP_anticodon

# Drug_Target_13_Protein_Sequence:
>Probable prolyl-tRNA synthetase, mitochondrial
MEGLLTRCRALPALATCSRQLSGYVPCRFHHCAPRRGRRLLLSRVFQPQNLREDRVLSLQ
DKSDDLTCKSQRLMLQVGLIYPASPGCYHLLPYTVRAMEKLVRVIDQEMQAIGGQKVNMP
SLSPAELWQATNRWDLMGKELLRLRDRHGKEYCLGPTHEEAITALIASQKKLSYKQLPFL
LYQVTRKFRDEPRPRFGLLRGREFYMKDMYTFDSSPEAAQQTYSLVCDAYCSLFNKLGLP
FVKVQADVGTIGGTVSHEFQLPVDIGEDRLAICPRCSFSANMETLDLSQMNCPACQGPLT
KTKGIEVGHTFYLGTKYSSIFNAQFTNVCGKPTLAEMGCYGLGVTRILAAAIEVLSTEDC
VRWPSLLAPYQACLIPPKKGSKEQAASELIGQLYDHITEAVPQLHGEVLLDDRTHLTIGN
RLKDANKFGYPFVIIAGKRALEDPAHFEVWCQNTGEVAFLTKDGVMDLLTPVQTV

# Drug_Target_13_Reaction:
ATP + L-proline + tRNAPro = AMP + diphosphate + L-prolyl-tRNAPro

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
ATP + L-proline + tRNA(Pro) = AMP + diphosphate + L-prolyl-tRNA(Pro)

# Drug_Target_13_SwissProt_ID:
Q7L3T8

# Drug_Target_13_SwissProt_Name:
SYPM_HUMAN

# Drug_Target_13_Synonyms:
EC 6.1.1.15
ProRS
Probable prolyl-tRNA synthetase, mitochondrial precursor
Proline--tRNA ligase

# Drug_Target_13_Theoretical_pI:
8.17

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Endoplasmic reticulum

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
LEPREL1

# Drug_Target_14_GenBank_ID_Gene:
AJ430351

# Drug_Target_14_GenBank_ID_Protein:
27526730

# Drug_Target_14_GeneCard_ID:
LEPREL1

# Drug_Target_14_Gene_Name:
LEPREL1

# Drug_Target_14_Gene_Sequence:
>2127 bp
ATGCGGGAGCGCATCTGGGCGCCGCCGCTGCTGCTGCTGCTGCCGCTGCTACTGCCGCCG
CCACTGTGGGGCGGCCCCCCGGACAGCCCACGCCGGGAGCTGGAGCTGGAGCCCGGGCCT
CTGCAGCCCTTCGACCTGCTCTACGCCAGCGGCGCGGCCGCCTACTACAGCGGAGACTAC
GAGCGAGCGGTGCGCGACTTGGAAGCGGCGCTGCGCAGCCACCGGCGCCTGCGGGAAATC
CGCACGCGCTGTGCCCGCCACTGCGCGGCGCGCCACCCGCTCCCGCCCCCGCCCCCCGGC
GAGGGCCCCGGCGCTGAGCTGCCCCTTTTCCGCTCCTTGTTGGGGCGGGCGCGCTGTTAT
CGCAGCTGTGAGACCCAGCGCCTCGGGGGCCCCGCATCCCGCCACCGCGTCAGCGAGGAT
GTGCGCAGCGACTTCCAGCGCAGAGTGCCCTACAACTACCTGCAGCGGGCCTACATCAAG
CTTAACCAGCTCGAAAAAGCAGTGGAAGCAGCTCACACATTTTTCGTGGCTAACCCTGAG
CACATGGAAATGCAGCAGAACATTGAGAATTACAGGGCGACAGCTGGTGTTGAAGCATTG
CAGTTGGTAGACAGAGAAGCCAAGCCACACATGGAGAGTTACAATGCAGGAGTTAAACAT
TATGAGGCTGATGACTTTGAGATGGCTATCAGGCATTTCGAACAAGCCTTAAGAGAATAT
TTCGTTGAAGATACAGAATGCCGGACCCTATGTGAGGGGCCTCAGAGATTTGAAGAATAT
GAGTATTTAGGGTATAAGGCTGGTCTGTATGAAGCTATTGCAGATCACTACATGCAGGTG
CTTGTTTGTCAGCATGAATGTGTGAGGGAACTTGCCACCCGCCCTGGCCGCCTCTCTCCC
ATCGAGAATTTTCTTCCTCTGCACTATGATTACCTACAGTTTGCCTACTATCGAGTTGGT
GAGTATGTGAAAGCCCTGGAGTGTGCCAAAGCCTATCTTCTATGCCATCCAGATGATGAG
GATGTCCTAGACAATGTGGATTACTATGAGAGTCTGCTGGATGATAGCATTGACCCGGCA
TCCATTGAGGCCAGAGAGGATTTAACAATGTTTGTGAAACGTCATAAGCTGGAGTCTGAG
CTGATAAAATCAGCTGCAGAAGGTCTGGGGTTTTCATACACTGAACCGAATTATTGGATC
AGATATGGAGGACGACAGGATGAGAATCGGGTCCCTTCAGGAGTGAACGTAGAGGGAGCA
GAAGTTCATGGATTCTCAATGGGAAAAAAGCTATCACCCAAGATAGATCGAGACCTAAGA
GAAGGTGGTCCTCTACTCTATGAGAACATCACATTCGTCTACAACTCGGAGCAGCTGAAC
GGGACTCAGCGGGTTCTCCTGGATAACGTCCTGTCGGAAGAACAGTGCCGGGAGCTCCAC
AGCGTGGCCAGTGGAATCATGCTTGTTGGTGATGGATACAGAGGAAAAACTTCACCCCAT
ACACCCAATGAAAAGTTTGAAGGTGCAACTGTCCTGAAAGCACTCAAATCTGGTTATGAA
GGTCGAGTCCCACTGAAGAGCGCTCGTCTGTTTTATGACATCAGCGAAAAGGCTCGAAGG
ATTGTAGAATCTTATTTTATGCTGAACTCAACTCTGTATTTTTCCTATACACACATGGTC
TGCCGAACAGCCCTGTCTGGTCAGCAGGATAGAAGAAATGACCTCAGTCATCCCATCCAT
GCTGACAACTGTTTGTTGGATCCAGAGGCCAACGAATGCTGGAAGGAGCCTCCTGCTTAC
ACATTTCGAGACTATAGTGCTCTCCTATATATGAATGATGACTTTGAAGGAGGAGAATTC
ATATTCACAGAGATGGATGCTAAGACTGTGACTGCCTCTATAAAACCAAAATGTGGGCGC
ATGATCAGCTTCTCATCTGGAGGAGAGAACCCTCATGGGGTGAAGGCAGTCACCAAGGGA
AAGAGGTGTGCTGTGGCTCTGTGGTTCACCTTGGACCCACTTTATAGAGAATTGGAGCGA
ATACAGGCTGATGAAGTGATTGCAATTCTGGATCAAGAACAGCAAGGGAAGCATGAACTG
AATATCAACCCTAAAGATGAGCTATAA

# Drug_Target_14_General_Function:
Not Available

# Drug_Target_14_General_References:
Not Available

# Drug_Target_14_HGNC_ID:
HGNC:19317

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
3949

# Drug_Target_14_Locus:
3q28

# Drug_Target_14_Molecular_Weight:
80985

# Drug_Target_14_Name:
Prolyl 3-hydroxylase 2

# Drug_Target_14_Number_of_Residues:
708

# Drug_Target_14_PDB_ID:
Not Available

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF03171	2OG-FeII_Oxy
PF07719	TPR_2

# Drug_Target_14_Protein_Sequence:
>Prolyl 3-hydroxylase 2
MRERIWAPPLLLLLPLLLPPPLWGGPPDSPRRELELEPGPLQPFDLLYASGAAAYYSGDY
ERAVRDLEAALRSHRRLREIRTRCARHCAARHPLPPPPPGEGPGAELPLFRSLLGRARCY
RSCETQRLGGPASRHRVSEDVRSDFQRRVPYNYLQRAYIKLNQLEKAVEAAHTFFVANPE
HMEMQQNIENYRATAGVEALQLVDREAKPHMESYNAGVKHYEADDFEMAIRHFEQALREY
FVEDTECRTLCEGPQRFEEYEYLGYKAGLYEAIADHYMQVLVCQHECVRELATRPGRLSP
IENFLPLHYDYLQFAYYRVGEYVKALECAKAYLLCHPDDEDVLDNVDYYESLLDDSIDPA
SIEAREDLTMFVKRHKLESELIKSAAEGLGFSYTEPNYWIRYGGRQDENRVPSGVNVEGA
EVHGFSMGKKLSPKIDRDLREGGPLLYENITFVYNSEQLNGTQRVLLDNVLSEEQCRELH
SVASGIMLVGDGYRGKTSPHTPNEKFEGATVLKALKSGYEGRVPLKSARLFYDISEKARR
IVESYFMLNSTLYFSYTHMVCRTALSGQQDRRNDLSHPIHADNCLLDPEANECWKEPPAY
TFRDYSALLYMNDDFEGGEFIFTEMDAKTVTASIKPKCGRMISFSSGGENPHGVKAVTKG
KRCAVALWFTLDPLYRELERIQADEVIAILDQEQQGKHELNINPKDEL

# Drug_Target_14_Reaction:
procollagen L-proline + 2-oxoglutarate + O2 = procollagen trans-3-hydroxy-L-proline + succinate + CO2

# Drug_Target_14_Signals:
1-24

# Drug_Target_14_Specific_Function:
Has prolyl 3-hydroxylase activity catalyzing the posttranslational formation of 3-hydroxyproline in -Xaa-Pro-Gly- sequences in collagens, especially types IV and V

# Drug_Target_14_SwissProt_ID:
Q8IVL5

# Drug_Target_14_SwissProt_Name:
P3H2_HUMAN

# Drug_Target_14_Synonyms:
EC 1.14.11.7
Leprecan-like protein 1
Myxoid liposarcoma-associated protein 4
Prolyl 3-hydroxylase 2 precursor

# Drug_Target_14_Theoretical_pI:
5.47

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Endoplasmic reticulum

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
LEPREL2

# Drug_Target_15_GenBank_ID_Gene:
U47924

# Drug_Target_15_GenBank_ID_Protein:
1200503

# Drug_Target_15_GeneCard_ID:
LEPREL2

# Drug_Target_15_Gene_Name:
LEPREL2

# Drug_Target_15_Gene_Sequence:
>2211 bp
ATGCTCCGGCTCCTCCGGCCGCTGCTGCTACTGCTGCTGCTGCCTCCCCCGGGGTCCCCT
GAGCCCCCCGGCCTGACCCAGCTGTCCCCGGGGGCGCCCCCGCAGGCCCCCGACTTGCTC
TACGCTGACGGGCTGCGCGCCTACGCGGCCGGGGCTTGGGCGCCGGCCGTGGCGCTGCTG
CGGGAGGCGCTGCGGAGCCAGGCGGCGCTGGGCCGGGTGCGGCTGGATTGCGGGGCGAGC
TGCGCGGCCGATCCGGGCGCCGCGCTCCCCGCCGTGCTTCTCGGGGCCCCGGAGCCCGAC
TCCGGGCCGGGACCCACGCAGGGGTCCTGGGAGCGACAGCTTCTCCGTGCAGCGCTCCGC
CGCGCAGACTGCCTGACCCAGTGCGCAGCACGGAGGCTGGGCCCCGGGGGCGCGGCGCGG
CTTCGCGTGGGGAGCGCGCTCCGGGACGCCTTCCGCCGTCGGGAGCCCTACAACTACCTG
CAGAGGGCCTATTACCAGTTGAAGAAGCTGGATCTGGCAGCTGCGGCAGCACACACCTTC
TTTGTAGCAAACCCCATGCACCTGCAGATGCGGGAGGACATGGCTAAGTACAGACGAATG
TCGGGAGTTCGGCCCCAGAGCTTCCGGGACCTGGAGACGCCCCCACACTGGGCAGCCTAT
GACACTGGCCTGGAGCTACTGGGGCGCCAGGAGGCAGGACTGGCACTGCCCAGGCTAGAG
GAGGCTCTTCAGGGGAGCCTGGCCCAGATGGAGAGCTGCCGTGCTGACTGTGAGGGGCCT
GAGGAGCAGCAGGGGGCTGAAGAAGAGGAGGATGGGGCTGCGAGCCAGGGGGGCCTCTAT
GAGGCCATTGCAGGACACTGGATTCAGGTCCTGCAGTGCCGGCAACGCTGTGTGGGGGAA
ACAGCCACACGCCCTGGTCGCAGCTTCCCTGTCCCAGACTTCCTTCCCAACCAGCTGAGG
CGGCTACATGAGGCCCATGCTCAGGTGGGCAATCTGTCCCAGGCTATAGAAAATGTCCTG
AGTGTCCTGCTCTTCTACCCGGAGGATGAGGCTGCCAAGAGGGCTCTGAACCAGTACCAG
GCCCAGCTGGGAGAGCCGAGACCTGGCCTCGGACCCAGAGAGGACATCCAGCGCTTCATC
CTCCGATCCCTGGGGGAGAAGAGGCAGCTCTACTATGCCATGGAGCACCTGGGGACCAGC
TTCAAGGATCCTGACCCCTGGACCCCTGCAGCTCTCATCCCTGAGGCACTTAGAGAAAAG
CTCAGAGAGGATCAAGAGAAGAGGCCTTGGGACCATGAGCCCGTGAAGCCAAAGCCCTTG
ACCTACTGGAAGGATGTCCTTCTCCTGGAGGGTGTGACCTTGACCCAGGATTCCAGGCAG
CTGAATGGGTCGGAGCGGGCGGTGTTGGATGGGCTGCTCACCCCAGCCGAGTGTGGGGTG
CTGCTGCAGCTGGCTAAGGATGCAGCTGGGGCTGGAGCCAGGTCTGGCTATCGTGGTCGC
CGCTCCCCTCACACCCCCCATGAACGCTTCGAGGGGCTCACGGTGCTTAAGGCTGCGCAG
CTGGCCCGGGCTGGGACAGTGGGCAGTCAGGGTGCTAAGCTGCTTCTGGAGGTGAGCGAG
CGGGTGCGGACCTTGACCCAGGCCTACTTCTCCCCGGAACGGCCCCTGCATCTGTCCTTC
ACCCACCTGGTGTGCCGCAGCGCCATAGAAGGAGAGCAAGAGCAGCGCATGGACCTGAGT
CACCCAGTGCACGCAGACAACTGCGTCCTGGACCCTGACACGGGAGAGTGCTGGCGGGAG
CCCCCAGCCTACACCTATCGGGACTACAGCGGACTCCTCTACCTCAACGATGACTTCCAG
GGTGGGGACCTGTTCTTCACGGAGCCCAACGCCCTCACTGTCACGGCTCGGGTGCGTCCT
CGCTGTGGGCGCCTTGTGGCCTTCAGCTCCGGTGTCGAGAATCCCCATGGGGTGTGGGCC
GTGACTCGGGGACGGCGCTGTGCCCTGGCACTGTGGCACACGTGGGCACCTGAGCACAGG
GAGCAGGAGTGGATAGAAGCCAAAGAACTGCTGCAGGAGTCACAGGAGGAGGAGGAAGAG
GAAGAGGAAGAAATGCCCAGCAAAGACCCTTCCCCAGAGCCCCCTAGCCGCAGGCACCAG
AGGGTCCAAGACAAGACTGGAAGGGCACCTCGGGTTCGGGAGGAGCTGTGA

# Drug_Target_15_General_Function:
Not Available

# Drug_Target_15_General_References:
8723724	Ansari-Lari MA, Muzny DM, Lu J, Lu F, Lilley CE, Spanos S, Malley T, Gibbs RA: A gene-rich cluster between the CD4 and triosephosphate isomerase genes at human chromosome 12p13. Genome Res. 1996 Apr;6(4):314-26.
9074930	Ansari-Lari MA, Shen Y, Muzny DM, Lee W, Gibbs RA: Large-scale sequencing in human chromosome 12p13: experimental and computational gene structure determination. Genome Res. 1997 Mar;7(3):268-80.

# Drug_Target_15_HGNC_ID:
HGNC:19318

# Drug_Target_15_HPRD_ID:
Not Available

# Drug_Target_15_ID:
3951

# Drug_Target_15_Locus:
12q13

# Drug_Target_15_Molecular_Weight:
81837

# Drug_Target_15_Name:
Prolyl 3-hydroxylase 3

# Drug_Target_15_Number_of_Residues:
736

# Drug_Target_15_PDB_ID:
Not Available

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
PF03171	2OG-FeII_Oxy

# Drug_Target_15_Protein_Sequence:
>Prolyl 3-hydroxylase 3
MLRLLRPLLLLLLLPPPGSPEPPGLTQLSPGAPPQAPDLLYADGLRAYAAGAWAPAVALL
REALRSQAALGRVRLDCGASCAADPGAALPAVLLGAPEPDSGPGPTQGSWERQLLRAALR
RADCLTQCAARRLGPGGAARLRVGSALRDAFRRREPYNYLQRAYYQLKKLDLAAAAAHTF
FVANPMHLQMREDMAKYRRMSGVRPQSFRDLETPPHWAAYDTGLELLGRQEAGLALPRLE
EALQGSLAQMESCRADCEGPEEQQGAEEEEDGAASQGGLYEAIAGHWIQVLQCRQRCVGE
TATRPGRSFPVPDFLPNQLRRLHEAHAQVGNLSQAIENVLSVLLFYPEDEAAKRALNQYQ
AQLGEPRPGLGPREDIQRFILRSLGEKRQLYYAMEHLGTSFKDPDPWTPAALIPEALREK
LREDQEKRPWDHEPVKPKPLTYWKDVLLLEGVTLTQDSRQLNGSERAVLDGLLTPAECGV
LLQLAKDAAGAGARSGYRGRRSPHTPHERFEGLTVLKAAQLARAGTVGSQGAKLLLEVSE
RVRTLTQAYFSPERPLHLSFTHLVCRSAIEGEQEQRMDLSHPVHADNCVLDPDTGECWRE
PPAYTYRDYSGLLYLNDDFQGGDLFFTEPNALTVTARVRPRCGRLVAFSSGVENPHGVWA
VTRGRRCALALWHTWAPEHREQEWIEAKELLQESQEEEEEEEEEMPSKDPSPEPPSRRHQ
RVQDKTGRAPRVREEL

# Drug_Target_15_Reaction:
procollagen L-proline + 2-oxoglutarate + O2 = procollagen trans-3-hydroxy-L-proline + succinate + CO2

# Drug_Target_15_Signals:
1-20

# Drug_Target_15_Specific_Function:
Has prolyl 3-hydroxylase activity catalyzing the posttranslational formation of 3-hydroxyproline in -Xaa-Pro-Gly- sequences in collagens, especially types IV and V

# Drug_Target_15_SwissProt_ID:
Q8IVL6

# Drug_Target_15_SwissProt_Name:
P3H3_HUMAN

# Drug_Target_15_Synonyms:
EC 1.14.11.7
Leprecan-like protein 2
Prolyl 3-hydroxylase 3 precursor
Protein B

# Drug_Target_15_Theoretical_pI:
6.26

# Drug_Target_15_Transmembrane_Regions:
None

# Drug_Target_16_Cellular_Location:
Not Available

# Drug_Target_16_Chromosome_Location:
Not Available

# Drug_Target_16_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
Not Available

# Drug_Target_16_GenBank_ID_Gene:
Not Available

# Drug_Target_16_GenBank_ID_Protein:
Not Available

# Drug_Target_16_GeneCard_ID:
Not Available

# Drug_Target_16_Gene_Name:
PYCRL

# Drug_Target_16_Gene_Sequence:
Not Available

# Drug_Target_16_General_Function:
Not Available

# Drug_Target_16_General_References:
Not Available

# Drug_Target_16_HGNC_ID:
Not Available

# Drug_Target_16_HPRD_ID:
Not Available

# Drug_Target_16_ID:
7125

# Drug_Target_16_Locus:
Not Available

# Drug_Target_16_Molecular_Weight:
Not Available

# Drug_Target_16_Name:
Pyrroline-5-carboxylate reductase 3

# Drug_Target_16_Number_of_Residues:
0

# Drug_Target_16_PDB_ID:
Not Available

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
Not Available

# Drug_Target_16_Protein_Sequence:
Not Available

# Drug_Target_16_Reaction:
Not Available

# Drug_Target_16_Signals:
Not Available

# Drug_Target_16_Specific_Function:
Not Available

# Drug_Target_16_SwissProt_ID:
Q53H96

# Drug_Target_16_SwissProt_Name:
P5CR3_HUMAN

# Drug_Target_16_Synonyms:
Not Available

# Drug_Target_16_Theoretical_pI:
Not Available

# Drug_Target_16_Transmembrane_Regions:
Not Available

# Drug_Target_17_Cellular_Location:
Not Available

# Drug_Target_17_Chromosome_Location:
Not Available

# Drug_Target_17_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
C14orf149

# Drug_Target_17_GenBank_ID_Gene:
BC012131

# Drug_Target_17_GenBank_ID_Protein:
15082426

# Drug_Target_17_GeneCard_ID:
C14orf149

# Drug_Target_17_Gene_Name:
C14orf149

# Drug_Target_17_Gene_Sequence:
>1065 bp
ATGGAGAGCGCGCTGGCGGTGCCCTGGCTGCCCCCGCATGATCCAGGGACGCCGGTGCTG
TCGGTGGTGGACATGCACACGGGCGGCGAGCCCTTGCGTATCGTGCTGGCGGGGTGTCCG
GAGGTGTCTGGGCCCACCCTGCTGGCCAAGCGGCGCTACATGCGCCAGCACCTTGACCAC
GTGCGGCGACGGCTCATGTTCGAGCCCCGAGGGCACCGGGACATGTACGGGGCGGTCCTA
GTCCCGAGCGAGCTGCCGGACGCGCATCTGGGCGTCCTGTTCCTGCACAACGAGGGCTAC
AGCTCCATGTGCGGCCACGCAGTGCTGGCGCTGGGCCGCTTCGCTTTGGACTTCGGGCTT
GTGCCGGCGCCCCCTGCGGGCACCCGCGAGGCCCGCGTCAATATCCACTGCCCCTGCGGG
CTGGTGACCGCCTTCGTGGCATGCGAGGACGGCCGCAGCCACGGACCGGTGCGCTTCCAC
AGCGTCCCGGCCTTCGTGCTGGCCACAGATCTCATGGTGGATGTTCCTGGACATGGAAAG
GTGATGGTGGACATTGCATATGGCGGTGCATTTTATGCATTTGTTACTGCTGAAAAGTTA
GGACTAGACATTTGTTCTGCAAAGACCAGGGACCTTGTGGATGCAGCGAGTGCAGTGACA
GAGGCAGTGAAAGCTCAGTTTAAAATTAATCATCCTGATAGTGAAGACCTTGCCTTTTTA
TATGGAACTATATTAACAGATGGAAAAGATGCTTATACCAAGGAACCAACCACCAACATT
TGTGTTTTTGCAGATGAACAGGTTGACAGAAGTCCCACTGGCTCAGGAGTGACAGCCCGA
ATTGCCTTACAGTATCACAAAGGGCTTCTGGAACTGAACCAGATGAGAGCCTTCAAAAGC
AGTGCAACTGGCTCAGTATTCACAGGGAAAGCTGTGAGGGAAGCGAAATGTGGTGATTTT
AAAGCTGTTATAGTGGAAGTATCAGGACAAGCCCATTACACGGGTACAGCAAGCTTTATA
ATAGAAGATGACGACCCATTGAGGGATGGATTTCTTCTCAAGTGA

# Drug_Target_17_General_Function:
Not Available

# Drug_Target_17_General_References:
12477932	Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat NK, Hopkins RF, Jordan H, Moore T, Max SI, Wang J, Hsieh F, Diatchenko L, Marusina K, Farmer AA, Rubin GM, Hong L, Stapleton M, Soares MB, Bonaldo MF, Casavant TL, Scheetz TE, Brownstein MJ, Usdin TB, Toshiyuki S, Carninci P, Prange C, Raha SS, Loquellano NA, Peters GJ, Abramson RD, Mullahy SJ, Bosak SA, McEwan PJ, McKernan KJ, Malek JA, Gunaratne PH, Richards S, Worley KC, Hale S, Garcia AM, Gay LJ, Hulyk SW, Villalon DK, Muzny DM, Sodergren EJ, Lu X, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madan A, Young AC, Shevchenko Y, Bouffard GG, Blakesley RW, Touchman JW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Krzywinski MI, Skalska U, Smailus DE, Schnerch A, Schein JE, Jones SJ, Marra MA: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16899-903. Epub 2002 Dec 11.

# Drug_Target_17_HGNC_ID:
HGNC:20488

# Drug_Target_17_HPRD_ID:
Not Available

# Drug_Target_17_ID:
4090

# Drug_Target_17_Locus:
14q23.1

# Drug_Target_17_Molecular_Weight:
38168

# Drug_Target_17_Name:
Chromosome 14 open reading frame 149

# Drug_Target_17_Number_of_Residues:
354

# Drug_Target_17_PDB_ID:
Not Available

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
PF05544	Pro_racemase

# Drug_Target_17_Protein_Sequence:
>Chromosome 14 open reading frame 149
MESALAVPWLPPHDPGTPVLSVVDMHTGGEPLRIVLAGCPEVSGPTLLAKRRYMRQHLDH
VRRRLMFEPRGHRDMYGAVLVPSELPDAHLGVLFLHNEGYSSMCGHAVLALGRFALDFGL
VPAPPAGTREARVNIHCPCGLVTAFVACEDGRSHGPVRFHSVPAFVLATDLMVDVPGHGK
VMVDIAYGGAFYAFVTAEKLGLDICSAKTRDLVDAASAVTEAVKAQFKINHPDSEDLAFL
YGTILTDGKDAYTKEPTTNICVFADEQVDRSPTGSGVTARIALQYHKGLLELNQMRAFKS
SATGSVFTGKAVREAKCGDFKAVIVEVSGQAHYTGTASFIIEDDDPLRDGFLLK

# Drug_Target_17_Reaction:
Not Available

# Drug_Target_17_Signals:
None

# Drug_Target_17_Specific_Function:
Not Available

# Drug_Target_17_SwissProt_ID:
Q96EM0

# Drug_Target_17_SwissProt_Name:
PRCM_HUMAN

# Drug_Target_17_Synonyms:
Not Available

# Drug_Target_17_Theoretical_pI:
6.56

# Drug_Target_17_Transmembrane_Regions:
None

# Drug_Target_18_Cellular_Location:
Not Available

# Drug_Target_18_Chromosome_Location:
Not Available

# Drug_Target_18_Drug_References:
16600630	Meng Z, Lou Z, Liu Z, Hui D, Bartlam M, Rao Z: Purification, characterization, and crystallization of human pyrroline-5-carboxylate reductase. Protein Expr Purif. 2006 Sep;49(1):83-7. Epub 2006 Mar 20.
16874462	Hu CA, Donald SP, Yu J, Lin WW, Liu Z, Steel G, Obie C, Valle D, Phang JM: Overexpression of proline oxidase induces proline-dependent and mitochondria-mediated apoptosis. Mol Cell Biochem. 2007 Jan;295(1-2):85-92. Epub 2006 Jul 28.
17536821	Huang TC, Huang YW, Hung HJ, Ho CT, Wu ML: Delta1-pyrroline-5-carboxylic acid formed by proline dehydrogenase from the Bacillus subtilis ssp. natto expressed in Escherichia coli as a precursor for 2-acetyl-1-pyrroline. J Agric Food Chem. 2007 Jun 27;55(13):5097-102. Epub 2007 May 31.

# Drug_Target_18_Essentiality:
Non-Essential

# Drug_Target_18_GenAtlas_ID:
PYCR1

# Drug_Target_18_GenBank_ID_Gene:
M77836

# Drug_Target_18_GenBank_ID_Protein:
189498

# Drug_Target_18_GeneCard_ID:
PYCR1

# Drug_Target_18_Gene_Name:
PYCR1

# Drug_Target_18_Gene_Sequence:
>960 bp
ATGAGCGTGGGCTTCATCGGCGCTGGCCAGCTGGCTTTTGCCCTGGCCAAGGGCTTCACA
GCAGCAGGCGTCTTGGCTGCCCACAAGATAATGGCTAGCTCCCCAGACATGGACCTGGCC
ACAGTTTCTGCTCTCAGGAAGATGGGGGTGAAGTTGACACCCCACAACAAGGAGACGGTG
CAGCACAGTGATGTGCTCTTCCTGGCTGTGAAGCCACACATCATCCCCTTCATCCTGGAT
GAAATAGGCGCCGACATTGAGGACAGACACATTGTGGTGTCCTGCGCGGCCGGCGTCACC
ATCAGCTCCATTGAGAAGAAGCTGTCAGCGTTTCGGCCAGCCCCCAGGGTCATCCGCTGC
ATGACCAACACTCCAGTCGTGGTGCGGGAGGGGGCCACCGTGTATGCCACAGGCACGCAC
GCCCAGGTGGAGGACGGGAGGCTCATGGAGCAGCTGCTGAGCACGGTGGGCTTCTGCACG
GAGGTGGAAGAGGACCTGATTGATGCCGTCACGGGGCTCAGTGGCAGCGGCCCCGCCTAC
GCATTCACAGCCCTGGATGCCCTGGCTGATGGGGGTGTGAAGATGGGACTTCCAAGGCGC
CTGGCAGTCCGCCTCGGGGCCCAGGCCCTCCTGGGGGCTGCCAAGATGCTGCTGCACTCA
GAACAGCACCCAGGCCAGCTCAAGGACAACGTCAGCTCTCCTGGTGGGGCCACCATCCAT
GCCTTGCATGTGCTGGAGAGTGGGGGCTTCCGCTCCCTGCTCATCAACGCTGTGGAGGCC
TCCTGCATCCGCACACGGGAGCTGCAGTCCATGGCTGACCAGGAGCAGGTGTCACCAGCC
GCCATCAAGAAGACCATCCTGGACAAGGTGAAGCTGGACTCCCCTGCAGGGACCGCTCTG
TCGCCTTCTGGCCACACCAAGCTGCTCCCCCGCAGCCTGGCCCCAGCGGGCAAGGATTGA

# Drug_Target_18_General_Function:
Amino acid transport and metabolism

# Drug_Target_18_General_References:
1730675	Dougherty KM, Brandriss MC, Valle D: Cloning human pyrroline-5-carboxylate reductase cDNA by complementation in Saccharomyces cerevisiae. J Biol Chem. 1992 Jan 15;267(2):871-5.

# Drug_Target_18_HGNC_ID:
HGNC:9721

# Drug_Target_18_HPRD_ID:
01528

# Drug_Target_18_ID:
248

# Drug_Target_18_Locus:
17q25.3

# Drug_Target_18_Molecular_Weight:
33361

# Drug_Target_18_Name:
Pyrroline-5-carboxylate reductase 1

# Drug_Target_18_Number_of_Residues:
319

# Drug_Target_18_PDB_ID:
Not Available

# Drug_Target_18_Pathway:
Not Available

# Drug_Target_18_Pfam_Domain_Function:
PF03807	F420_oxidored

# Drug_Target_18_Protein_Sequence:
>Pyrroline-5-carboxylate reductase 1
MSVGFIGAGQLAFALAKGFTAAGVLAAHKIMASSPDMDLATVSALRKMGVKLTPHNKETV
QHSDVLFLAVKPHIIPFILDEIGADIEDRHIVVSCAAGVTISSIEKKLSAFRPAPRVIRC
MTNTPVVVREGATVYATGTHAQVEDGRLMEQLLSSVGFCTEVEEDLIDAVTGLSGSGPAY
AFTALDALADGGVKMGLPRRLAVRLGAQALLGAAKMLLHSEQHPGQLKDNVSSPGGATIH
ALHVLESGGFRSLLINAVEASCIRTRELQSMADQEQVSPAAIKKTILDKVKLDSPAGTAL
SPSGHTKLLPRSLAPAGKD

# Drug_Target_18_Reaction:
L-proline + NAD(P)+ = 1-pyrroline-5-carboxylate + NAD(P)H + H+

# Drug_Target_18_Signals:
None

# Drug_Target_18_Specific_Function:
Not Available

# Drug_Target_18_SwissProt_ID:
P32322

# Drug_Target_18_SwissProt_Name:
P5CR1_HUMAN

# Drug_Target_18_Synonyms:
EC 1.5.1.2
P5C reductase 1
P5CR 1

# Drug_Target_18_Theoretical_pI:
7.69

# Drug_Target_18_Transmembrane_Regions:
None

# Drug_Target_19_Cellular_Location:
Not Available

# Drug_Target_19_Chromosome_Location:
Not Available

# Drug_Target_19_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_19_Essentiality:
Non-Essential

# Drug_Target_19_GenAtlas_ID:
EPRS

# Drug_Target_19_GenBank_ID_Gene:
X54326

# Drug_Target_19_GenBank_ID_Protein:
31958

# Drug_Target_19_GeneCard_ID:
EPRS

# Drug_Target_19_Gene_Name:
EPRS

# Drug_Target_19_Gene_Sequence:
>4323 bp
ATGGAACATACTGAGATTGATCACTGGTTGGAGTTCAGTGCTACAAAATTATCTTCATGT
GATTCCTTTACTTCTACAATTAATGAACTCAATCATTGCCTGTCTCTGAGAACATACTTA
GTTGGAAACTCCTTGAGTTTAGCAGATTTATGTGTTTGGGCCACCCTAAAAGGAAATGCT
GCCTGGCAAGAACAGTTGAAACAGAAGAAAGCTCCAGTTCATGTAAAACGTTGGTTTGGC
TTTCTTGAAGCCCAGCAGGCCTTCCAGTCAGTAGGTACCAAGTGGGATGTTTCAACAACC
AAAGCTCGAGTGGCACCTGAGAAAAAGCAAGATGTTGGGAAATTTGTTGAGCTTCCAGGT
GCGGAGATGGGAAAGGTTACCGTCAGATTTCCTCCAGAGGCCAGTGGTTACTTACACATT
GGGCATGCAAAAGCTGCTCTTCTGAACCAGCACTACCAGGTTAACTTTAAAGGGAAACTG
ATCATGAGATTTGATGACACAAATCCTGAAAAAGAAAAGGAAGATTTTGAGAAGGTTATC
TTGGAAGATGTTGCAATGTTGCATATCAAACCAGATCAATTTACTTATACTTCGGATCAT
TTTGAAACTATAATGAAGTATGCAGAGAAGCTAATTCAAGAAGGGAAGGCTTATGTGGAT
GATACTCCTGCTGAACAGATGAAAGCAGAACGTGAGCAGAGGATAGAATCTAAACATAGA
AAAAACCCTATTGAGAAGAATCTACAAATGTGGGAAGAAATGAAAAAAGGGAGCCAGTTT
GGTCACTCCTGTTGTTTGCGAGCAAAAATTGACATGAGTAGTAACAATGGATGCATGAGA
GATCCAACCCTTTATCGCTGCAAAATTCAACCACATCCAAGAACTGGAAATAAATACAAT
GTTTATCCAACATATGATTTTGCCTGCCCCATAGTTGACAGCATCGAAGGTGTTACACAT
GCCCTGAGAACAACAGAATACCATGACAGAGATGAGCAGTTTTACTGGATTATTGAAGCT
TTAGGCATAAGAAAACCATATATTTGGGAATATAGTCGGCTAAATCTCAACAACACAGTG
CTATCCAAAAGAAAACTCACATGGTTTGTCAATGAAGGACTAGTAGATGGATGGGATGAC
CCAAGATTTCCTACGGTTCGTGGTGTACTGAGAAGAGGGATGACAGTTGAAGGACTGAAA
CAGTTTATTGCTGCTCAGGGCTCCTCACGTTCAGTCGTGAACATGGAGTGGGACAAAATC
TGGGCGTTTAACAAAAAGGTTATTGACCCAGTGGCTCCACGATATGTTGCATTACTGAAG
AAAGAAGTGATCCCAGTGAATGTACCTGAAGCTCAGGAGGAGATGAAAGAAGTAGCCAAA
CACCCAAAGAATCCTGAGGTTGGCTTGAAGCCTGTGTGGTATAGTCCCAAAGTTTTCATT
GAAGGTGCTGATGCAGAGACTTTTTCGGAGGGTGAGATGGTTACATTTATAAATTGGGGC
AACCTCAACATTACAAAAATACACAAAAATGCAGATGGAAAAATCATATCTCTTGATGCA
AAGTTTAATTTGGAAAACAAAGACTACAAGAAAACCACTAAGGTCACTTGGCTTGCAGAG
ACTACACATGCTCTTCCTATTCCAGTAATCTGTGTCACTTATGAGCACTTGATCACAAAG
CCAGTGCTAGGAAAAGACGAGGACTTTAAGCAGTATGTCAACAAGAACAGTAAGCATGAA
GAGCTAATGCTAGGGGATCCCTGCCTTAAGGATTTGAAAAAAGGAGATATTATACAACTC
CAGAGAAGAGGATTCTTCATATGTGATCAACCTTATGAACCTGTTAGCCCATATAGTTGC
AAGGAAGCCCCGTGTGTTTTGATATACATTCCTGATGGGCACACAAAGGAAATGCCAACA
TCAGGGTCAAAGGAAAAGACCAAAGTAGAAGCCACAAAAAATGAGACCTCTGCTCCTTTT
AAGGAAAGACCAACACCTTCTCTGAATAATAATTGTACTACATCTGAGGATTCCTTGGTC
CTTTACAATAGAGTGGCTGTTCAAGGAGATGTGGTTCGTGAATTAAAAGCCAAGAAAGCA
CCAAAGGAAGATGTAGATGCAGCTGTAAAACAGCTTTTGTCTTTGAAAGCTGAATATAAG
GAGAAAACTGGCCAGGAATATAAACCTGGAAACCCTCCTGCTGAAATAGGACAGAATATT
TCTTCTAATTCCTCAGCAAGTATTCTGGAAAGTAAATCTCTGTATGATGAAGTTGCTGCA
CAAGGGGAGGTGGTTCGTAAGCTAAAAGCTGAAAAATCCCCTAAGGCTAAAATAAATGAA
GCTGTAGAATGCTTACTGTCCCTGAAGGCTCAGTATAAAGAAAAAACTGGGAAGGAGTAC
ATACCTGGTCAGCCCCCATTATCTCAAAGTTCGGATTCAAGCCCAACCAGAAATTCTGAA
CCTGCTGGTTTAGAAACACCAGAAGCGAAAGTACTTTTTGACAAAGTAGCTTCTCAAGGG
GAAGTAGTTCGGAAACTTAAAACTGAAAAAGCCCCTAAGGATCAAGTAGATATAGCTGTT
CAAGAACTCCTTCAGCTAAAGGCACAGTACAAGTCTTTGATAGGAGTAGAGTATAAGCCT
GTGTCGGCCACTGGAGCTGAGGACAAAGATAAGAAGAAGAAAGAAAAAGAAAATAAATCT
GAAAAGCAGAATAAGCCTCAGAAACAAAATGATGGCCAAAGGAAAGACCCTTCTAAAAAC
CAAGGAGGTGGGCTCTCATCAAGTGGAGCAGGAGAAGGGCAGGGGCCTAAGAAACAGACC
AGGTTGGGTCTTGAGGCAAAAAAAGAAGAAAATCTTGCTGATTGGTATTCTCAGGTCATC
ACAAAGTCAGAAATGATTGAATACCATGACATAAGTGGCTGTTATATTCTTCGTCCCTGG
GCCTATGCCATTTGGGAAGCCATCAAGGACTTTTTTGATGCTGAGATCAAGAAACTTGGT
GTTGAAAACTGCTACTTCCCCATGTTTGTGTCTCAAAGTGCATTAGAGAAAGAGAAGACT
CATGTTGCTGACTTTGCCCCAGAGGTTGCTTGGGTTACAAGATCTGGCAAAACCGAGCTG
GCAGAACCAATTGCCATTCGTCCTACTAGTGAAACAGTAATGTATCCTGCATATGCAAAA
TGGGTACAATCACACAGAGACCTGCCCATCAAGCTCAATCAGTGGTGCAATGTGGTGCGT
TGGGAATTCAAGCATCCTCAGCCTTTCCTACGTACTCGTGAATTTCTTTGGCAGGAAGGG
CACAGTGCTTTTGCTACCATGGAAGAGGCAGCGGAAGAGGTCTTGCAGATACTTGACTTA
TATGCTCAGGTATATGAAGAACTCCTGGCAATTCCTGTTGTTAAAGGAAGAAAGACGGAA
AAGGAAAAATTTGCAGGAGGAGACTATACAACTACAATAGAAGCATTTATATCTGCTAGT
GGAAGAGCTATCCAGGGAGGAACATCACATCATTTAGGGCAGAATTTTTCCAAAATGTTT
GAAATCGTTTTTGAAGATCCAAAGATACCAGGAGAGAAGCAATTTGCCTATCAAAACTCC
TGGGGCCTGACAACTCGAACTATTGGTGTTATGACCATGGTTCATGGGGACAACATGGGT
TTAGTATTACCACCCCGTGTAGCATGTGTTCAGGTGGTGATTATTCCTTGTGGCATTACC
AATGCACTTTCTGAAGAAGACAAAGAAGCGCTGATTGCAAAATGCAATGATTATCGAAGG
CGATTACTCAGTGTTAACATCCGCGTTAGAGCTGATTTACGAGATAATTATTCTCCAGGT
TGGAAATTCAATCACTGGGAGCTCAAGGGAGTTCCCATTAGACTTGAAGTTGGGCCACGT
GATATGAAGAGCTGTCAGTTTGTAGCCGTCAGACGAGATACTGGAGAAAAGCTGACAGTT
GCTGAAAATGAGGCAGAGACTAAACTTCAAGCTATTTTGGAAGACATCCAGGTCACCCTT
TTCACAAGGGCTTCTGAAGACCTTAAGACTCATATGGTTGTGGCTAATACAATGGAAGAC
TTTCAGAAGATACTAGATTCTGGAAAGATTGTTCAGATTCCATTCTGTGGGGAAATTGAC
TGTGAGGACTGGATCAAAAAGACCACTGCCAGGGATCAAGATCTTGAACCTGGTGCTCCA
TCCATGGGAGCTAAAAGCCTTTGCATCCCCTTCAAACCACTCTGTGAACTGCAGCCTGGA
GCCAAATGTGTCTGTGGCAAGAACCCTGCCAAGTACTACACCTTATTTGGTCGCAGCTAC
TGA

# Drug_Target_19_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_19_General_References:
11123902	Jeong EJ, Hwang GS, Kim KH, Kim MJ, Kim S, Kim KS: Structural analysis of multifunctional peptide motifs in human bifunctional tRNA synthetase: identification of RNA-binding residues and functional implications for tandem repeats. Biochemistry. 2000 Dec 26;39(51):15775-82.
1556743	Kaiser E, Eberhard D, Knippers R: Exons encoding the highly conserved part of human glutaminyl-tRNA synthetase. J Mol Evol. 1992 Jan;34(1):45-53.
1756734	Cerini C, Kerjan P, Astier M, Gratecos D, Mirande M, Semeriva M: A component of the multisynthetase complex is a multifunctional aminoacyl-tRNA synthetase. EMBO J. 1991 Dec;10(13):4267-77.
1988429	Fett R, Knippers R: The primary structure of human glutaminyl-tRNA synthetase. A highly conserved core, amino acid repeat regions, and homologies with translation elongation factors. J Biol Chem. 1991 Jan 25;266(3):1448-55.
3290852	Thommes P, Fett R, Schray B, Kunze N, Knippers R: The core region of human glutaminyl-tRNA synthetase homologies with the Escherichia coli and yeast enzymes. Nucleic Acids Res. 1988 Jun 24;16(12):5391-406.

# Drug_Target_19_HGNC_ID:
HGNC:3418

# Drug_Target_19_HPRD_ID:
00703

# Drug_Target_19_ID:
210

# Drug_Target_19_Locus:
1q41-q42

# Drug_Target_19_Molecular_Weight:
163028

# Drug_Target_19_Name:
Bifunctional aminoacyl-tRNA synthetase [Includes: Glutamyl-tRNA synthetase

# Drug_Target_19_Number_of_Residues:
1440

# Drug_Target_19_PDB_ID:
Not Available

# Drug_Target_19_Pathway:
Not Available

# Drug_Target_19_Pfam_Domain_Function:
PF00458	WHEP-TRS
PF00587	tRNA-synt_2b
PF00749	tRNA-synt_1c
PF03129	HGTP_anticodon
PF03950	tRNA-synt_1c_C

# Drug_Target_19_Protein_Sequence:
>Bifunctional aminoacyl-tRNA synthetase [Includes: Glutamyl-tRNA synthetase
MEHTEIDHWLEFSATKLSSCDSFTSTINELNHCLSLRTYLVGNSLSLADLCVWATLKGNA
AWQEQLKQKKAPVHVKRWFGFLEAQQAFQSVGTKWDVSTTKARVAPEKKQDVGKFVELPG
AEMGKVTVRFPPEASGYLHIGHAKAALLNQHYQVNFKGKLIMRFDDTNPEKEKEDFEKVI
LEDVAMLHIKPDQFTYTSDHFETIMKYAEKLIQEGKAYVDDTPAEQMKAEREQRIESKHR
KNPIEKNLQMWEEMKKGSQFGHSCCLRAKIDMSSNNGCMRDPTLYRCKIQPHPRTGNKYN
VYPTYDFACPIVDSIEGVTHALRTTEYHDRDEQFYWIIEALGIRKPYIWEYSRLNLNNTV
LSKRKLTWFVNEGLVDGWDDPRFPTVRGVLRRGMTVEGLKQFIAAQGSSRSVVNMEWDKI
WAFNKKVIDPVAPRYVALLKKEVIPVNVPEAQEEMKEVAKHPKNPEVGLKPVWYSPKVFI
EGADAETFSEGEMVTFINWGNLNITKIHKNADGKIISLDAKFNLENKDYKKTTKVTWLAE
TTHALPIPVICVTYEHLITKPVLGKDEDFKQYVNKNSKHEELMLGDPCLKDLKKGDIIQL
QRRGFFICDQPYEPVSPYSCKEAPCVLIYIPDGHTKEMPTSGSKEKTKVEATKNETSAPF
KERPTPSLNNNCTTSEDSLVLYNRVAVQGDVVRELKAKKAPKEDVDAAVKQLLSLKAEYK
EKTGQEYKPGNPPAEIGQNISSNSSASILESKSLYDEVAAQGEVVRKLKAEKSPKAKINE
AVECLLSLKAQYKEKTGKEYIPGQPPLSQSSDSSPTRNSEPAGLETPEAKVLFDKVASQG
EVVRKLKTEKAPKDQVDIAVQELLQLKAQYKSLIGVEYKPVSATGAEDKDKKKKEKENKS
EKQNKPQKQNDGQRKDPSKNQGGGLSSSGAGEGQGPKKQTRLGLEAKKEENLADWYSQVI
TKSEMIEYHDISGCYILRPWAYAIWEAIKDFFDAEIKKLGVENCYFPMFVSQSALEKEKT
HVADFAPEVAWVTRSGKTELAEPIAIRPTSETVMYPAYAKWVQSHRDLPIKLNQWCNVVR
WEFKHPQPFLRTREFLWQEGHSAFATMEEAAEEVLQILDLYAQVYEELLAIPVVKGRKTE
KEKFAGGDYTTTIEAFISASGRAIQGGTSHHLGQNFSKMFEIVFEDPKIPGEKQFAYQNS
WGLTTRTIGVMTMVHGDNMGLVLPPRVACVQVVIIPCGITNALSEEDKEALIAKCNDYRR
RLLSVNIRVRADLRDNYSPGWKFNHWELKGVPIRLEVGPRDMKSCQFVAVRRDTGEKLTV
AENEAETKLQAILEDIQVTLFTRASEDLKTHMVVANTMEDFQKILDSGKIVQIPFCGEID
CEDWIKKTTARDQDLEPGAPSMGAKSLCIPFKPLCELQPGAKCVCGKNPAKYYTLFGRSY

# Drug_Target_19_Reaction:
ATP + L-proline + tRNAPro = AMP + diphosphate + L-prolyl-tRNAPro

# Drug_Target_19_Signals:
None

# Drug_Target_19_Specific_Function:
Not Available

# Drug_Target_19_SwissProt_ID:
P07814

# Drug_Target_19_SwissProt_Name:
SYEP_HUMAN

# Drug_Target_19_Synonyms:
EC 6.1.1.15
EC 6.1.1.17
Glutamate--tRNA ligase
Prolyl-tRNA synthetase

# Drug_Target_19_Theoretical_pI:
7.75

# Drug_Target_19_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Endoplasmic reticulum

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
P4HA2

# Drug_Target_1_GenBank_ID_Gene:
U90441

# Drug_Target_1_GenBank_ID_Protein:
2439985

# Drug_Target_1_GeneCard_ID:
P4HA2

# Drug_Target_1_Gene_Name:
P4HA2

# Drug_Target_1_Gene_Sequence:
>1608 bp
ATGAAACTCTGGGTGTCTGCATTGCTGATGGCCTGGTTTGGTGTCCTGAGCTGTGTGCAG
GCCGAATTCTTCACCTCTATTGGGCACATGACTGACCTGATTTATGCAGAGAAAGAGCTG
GTGCAGTCTCTGAAAGAGTACATCCTTGTGGAGGAAGCCAAGCTTTCCAAGATTAAGAGC
TGGGCCAACAAAATGGAAGCCTTGACTAGCAAGTCAGCTGCTGATGCTGAGGGCTACCTG
GCTCACCCTGTGAATGCCTACAAACTGGTGAAGCGGCTAAACACAGACTGGCCTGCGCTG
GAGGACCTTGTCCTGCAGGACTCAGCTGCAGGTTTTATCGCCAACCTCTCTGTGCAGCGG
CAGTTCTTCCCCACTGATGAGGACGAGATAGGAGCTGCCAAAGCCCTGATGAGACTTCAG
GACACATACAGGCTGGACCCAGGCACAATTTCCAGAGGGGAACTTCCAGGAACCAAGTAC
CAGGCAATGCTGAGTGTGGATGACTGCTTTGGGATGGGCCGCTCGGCCTACAATGAAGGG
GACTATTATCATACGGTGTTGTGGATGGAGCAGGTGCTAAAGCAGCTTGATGCCGGGGAG
GAGGCCACCACAACCAAGTCACAGGTGCTGGACTACCTCAGCTATGCTGTCTTCCAGTTG
GGTGATCTGCACCGTGCCCTGGAGCTCACCCGCCGCCTGCTCTCCCTTGACCCAAGCCAC
GAACGAGCTGGAGGGAATCTGCGGTACTTTGAGCAGTTATTGGAGGAAGAGAGAGAAAAA
ACGTTAACAAATCAGACAGAAGCTGAGCTAGCAACCCCAGAAGGCATCTATGAGAGGCCT
GTGGACTACCTGCCTGAGAGGGATGTTTACGAGAGCCTCTGTCGTGGGGAGGGTGTCAAA
CTGACACCCCGTAGACAGAAGAGGCTTTTCTGTAGGTACCACCATGGCAACAGGGCCCCA
CAGCTGCTCATTGCCCCCTTCAAAGAGGAGGACGAGTGGGACAGCCCGCACATCGTCAGG
TACTACGATGTCATGTCTGATGAGGAAATCGAGAGGATCAAGGAGATCGCAAAACCTAAA
CTTGCACGAGCCACCGTTCGTGATCCCAAGACAGGAGTCCTCACTGTCGCCAGCTACCGG
GTTTCCAAAAGCTCCTGGCTAGAGGAAGATGATGACCCTGTTGTGGCCCGAGTAAATCGT
CGGATGCAGCATATCACAGGGTTAACAGTAAAGACTGCAGAATTGTTACAGGTTGCAAAT
TATGGAGTGGGAGGACAGTATGAACCGCACTTCGACTTCTCTAGGAATGATGAGCGAGAT
ACTTTCAAGCATTTAGGGACGGGGAATCGTGTGGCTACTTTCTTAAACTACATGAGTGAT
GTAGAAGCTGGTGGTGCCACCGTCTTCCCTGATCTGGGGGCTGCAATTTGGCCTAAGAAG
GGTACAGCTGTGTTCTGGTACAACCTCTTGCGGAGCGGGGAAGGTGACTACCGAACAAGA
CATGCTGCCTGCCCTGTGCTTGTGGGCTGCAAGTGGGTCTCCAATAAGTGGTTCCATGAA
CGAGGACAGGAGTTCTTGAGACCTTGTGGATCAACAGAAGTTGACTGA

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
11606192	Nokelainen M, Nissi R, Kukkola L, Helaakoski T, Myllyharju J: Characterization of the human and mouse genes for the alpha subunit of type II prolyl 4-hydroxylase. Identification of a previously unknown alternatively spliced exon and its expression in various tissues. Eur J Biochem. 2001 Oct;268(20):5300-9.
12975309	Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A: The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003 Oct;13(10):2265-70. Epub 2003 Sep 15.
9211872	Annunen P, Helaakoski T, Myllyharju J, Veijola J, Pihlajaniemi T, Kivirikko KI: Cloning of the human prolyl 4-hydroxylase alpha subunit isoform alpha(II) and characterization of the type II enzyme tetramer. The alpha(I) and alpha(II) subunits do not form a mixed alpha(I)alpha(II)beta2 tetramer. J Biol Chem. 1997 Jul 11;272(28):17342-8.

# Drug_Target_1_HGNC_ID:
HGNC:8547

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4000

# Drug_Target_1_Locus:
5q31

# Drug_Target_1_Molecular_Weight:
60903

# Drug_Target_1_Name:
Prolyl 4-hydroxylase subunit alpha-2

# Drug_Target_1_Number_of_Residues:
535

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF03171	2OG-FeII_Oxy
PF07719	TPR_2
PF08336	P4Ha_N

# Drug_Target_1_Protein_Sequence:
>Prolyl 4-hydroxylase subunit alpha-2
MKLWVSALLMAWFGVLSCVQAEFFTSIGHMTDLIYAEKELVQSLKEYILVEEAKLSKIKS
WANKMEALTSKSAADAEGYLAHPVNAYKLVKRLNTDWPALEDLVLQDSAAGFIANLSVQR
QFFPTDEDEIGAAKALMRLQDTYRLDPGTISRGELPGTKYQAMLSVDDCFGMGRSAYNEG
DYYHTVLWMEQVLKQLDAGEEATTTKSQVLDYLSYAVFQLGDLHRALELTRRLLSLDPSH
ERAGGNLRYFEQLLEEEREKTLTNQTEAELATPEGIYERPVDYLPERDVYESLCRGEGVK
LTPRRQKRLFCRYHHGNRAPQLLIAPFKEEDEWDSPHIVRYYDVMSDEEIERIKEIAKPK
LARATVRDPKTGVLTVASYRVSKSSWLEEDDDPVVARVNRRMQHITGLTVKTAELLQVAN
YGVGGQYEPHFDFSRNDERDTFKHLGTGNRVATFLNYMSDVEAGGATVFPDLGAAIWPKK
GTAVFWYNLLRSGEGDYRTRHAACPVLVGCKWVSNKWFHERGQEFLRPCGSTEVD

# Drug_Target_1_Reaction:
procollagen L-proline + 2-oxoglutarate + O2 = procollagen trans-4-hydroxy-L-proline + succinate + CO2

# Drug_Target_1_Signals:
1-21

# Drug_Target_1_Specific_Function:
Catalyzes the posttranslational formation of 4- hydroxyproline in -Xaa-Pro-Gly- sequences in collagens and other proteins

# Drug_Target_1_SwissProt_ID:
O15460

# Drug_Target_1_SwissProt_Name:
P4HA2_HUMAN

# Drug_Target_1_Synonyms:
4-PH alpha-2
EC 1.14.11.2
Procollagen-proline,2-oxoglutarate-4-dioxygenase alpha-2 subunit
Prolyl 4-hydroxylase subunit alpha-2 precursor

# Drug_Target_1_Theoretical_pI:
5.43

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_20_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_20_Chromosome_Location:
Not Available

# Drug_Target_20_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_20_Essentiality:
Non-Essential

# Drug_Target_20_GenAtlas_ID:
SLC6A14

# Drug_Target_20_GenBank_ID_Gene:
AF151978

# Drug_Target_20_GenBank_ID_Protein:
5732680

# Drug_Target_20_GeneCard_ID:
SLC6A14

# Drug_Target_20_Gene_Name:
SLC6A14

# Drug_Target_20_Gene_Sequence:
>1929 bp
ATGGACAAGTTGAAATGCCCGAGTTTCTTCAAGTGCAGGGAGAAGGAGAAAGTGTCGGCT
TCATCAGAGAATTTCCATGTTGGTGAAAATGATGAGAATCAGGACCGTGGTAACTGGTCC
AAAAAATCGGATTATCTTCTATCTATGATTGGATACGCAGTGGGATTAGGAAATGTGTGG
AGATTTCCATATCTGACCTACAGCAATGGTGGAGGCGCCTTCTTGATACCTTATGCAATT
ATGTTAGCATTGGCTGGTTTACCTTTGTTCTTTCTGGAGTGTTCACTGGGACAATTTGCT
AGCTTAGGTCCAGTTTCAGTTTGGAGGATTCTTCCATTGTTTCAAGGTGTGGGAATTACA
ATGGTCCTGATCTCCATTTTTGTGACAATCTATTACAATGTCATAATTGCCTATAGTCTT
TACTACATGTTTGCTTCTTTTCAAAGTGAACTACCATGGAAAAATTGTTCTTCGTGGTCA
GATAAAAACTGTAGCAGATCACCAATAGTAACTCACTGTAATGTGAGTACAGTGAATAAA
GGAATACAAGAGATCATCCAAATGAATAAAAGCTGGGTAGACATCAACAATTTTACCTGC
ATCAACGGCAGTGAAATTTATCAGCCAGGGCAGCTTCCCAGTGAACAATATTGGAATAAA
GTGGCGCTCCAACGGTCAAGTGGAATGAATGAGACTGGAGTAATTGTTTGGTATTTAGCA
CTTTGTCTTCTTCTGGCTTGGCTCATAGTTGGAGCAGCACTATTTAAAGGAATCAAATCG
TCTGGCAAGGTGGTATATTTTACAGCTCTTTTCCCCTATGTGGTCCTACTCATCCTGTTA
GTACGAGGTGCAACTCTGGAGGGTGCTTCAAAAGGCATTTCATACTATATTGGAGCCCAG
TCAAATTTTACAAAACTTAAGGAAGCTGAGGTATGGAAAGATGCTGCCACTCAGATATTT
TACTCCCTTTCAGTGGCTTGGGGTGGCTTAGTTGCTCTATCATCTTACAATAAGTTCAAA
AACAACTGCTTCTCTGATGCCATTGTGGTTTGTTTGACAAACTGTCTCACTAGCGTGTTT
GCTGGATTTGCTATTTTTTCTATATTGGGACACATGGCCCATATATCTGGAAAGGAAGTT
TCTCAAGTTGTAAAATCAGGTTTTGATTTGGCATTCATTGCCTATCCAGAGGCTCTAGCC
CAACTCCCAGGTGGTCCATTTTGGTCCATATTATTTTTTTTCATGCTTTTAACTTTGGGT
CTCGATTCTCAGTTTGCTTCGATTGAAACGATCACAACAACAATTCAAGATTTATTTCCC
AAAGTGATGAAGAAAATGAGGGTTCCCATAACTTTGGGCTGCTGCTTGGTTTTGTTTCTC
CTTGGTCTCGTCTGTGTGACTCAGGCTGGAATTTACTGGGTTCATCTGATTGACCACTTC
TGTGCTGGATGGGGCATTTTAATTGCAGCTATACTGGAGCTAGTTGGAATCATCTGGATT
TATGGAGGGAACAGATTCATTGAGGATACAGAAATGATGATTGGAGCAAAGAGGTGGATA
TTCTGGCTATGGTGGAGAGCTTGCTGGTTTGTAATTACGCCTATCCTTTTGATTGCAATA
TTTATCTGGTCATTGGTGCAATTTCATAGACCTAATTATGGCGCAATTCCATACCCTGAC
TGGGGAGTTGCTTTAGGCTGGTGTATGATTGTTTTCTGCATTATTTGGATACCAATTATG
GCTATCATAAAAATAATTCAGGCTAAAGGAAACATCTTTCAACGCCTTATAAGTTGCTGC
AGACCAGCTTCTAACTGGGGTCCATACCTGGAACAACATCGTGGGGAAAGATATAAAGAC
ATGGTAGATCCTAAAAAAGAGGCTGACCATGAAATACCTACTGTTAGTGGCAGCAGAAAA
CCGGAATGA

# Drug_Target_20_General_Function:
Involved in neurotransmitter:sodium symporter activity

# Drug_Target_20_General_References:
10446133	Sloan JL, Mager S: Cloning and functional expression of a human Na(+) and Cl(-)-dependent neutral and cationic amino acid transporter B(0+). J Biol Chem. 1999 Aug 20;274(34):23740-5.

# Drug_Target_20_HGNC_ID:
HGNC:11047

# Drug_Target_20_HPRD_ID:
02344

# Drug_Target_20_ID:
471

# Drug_Target_20_Locus:
Xq23-q24

# Drug_Target_20_Molecular_Weight:
72154

# Drug_Target_20_Name:
Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+)

# Drug_Target_20_Number_of_Residues:
642

# Drug_Target_20_PDB_ID:
Not Available

# Drug_Target_20_Pathway:
Not Available

# Drug_Target_20_Pfam_Domain_Function:
PF00209	SNF

# Drug_Target_20_Protein_Sequence:
>Sodium- and chloride-dependent neutral and basic amino acid transporter B(0+)
MDKLKCPSFFKCREKEKVSASSENFHVGENDENQDRGNWSKKSDYLLSMIGYAVGLGNVW
RFPYLTYSNGGGAFLIPYAIMLALAGLPLFFLECSLGQFASLGPVSVWRILPLFQGVGIT
MVLISIFVTIYYNVIIAYSLYYMFASFQSELPWKNCSSWSDKNCSRSPIVTHCNVSTVNK
GIQEIIQMNKSWVDINNFTCINGSEIYQPGQLPSEQYWNKVALQRSSGMNETGVIVWYLA
LCLLLAWLIVGAALFKGIKSSGKVVYFTALFPYVVLLILLVRGATLEGASKGISYYIGAQ
SNFTKLKEAEVWKDAATQIFYSLSVAWGGLVALSSYNKFKNNCFSDAIVVCLTNCLTSVF
AGFAIFSILGHMAHISGKEVSQVVKSGFDLAFIAYPEALAQLPGGPFWSILFFFMLLTLG
LDSQFASIETITTTIQDLFPKVMKKMRVPITLGCCLVLFLLGLVCVTQAGIYWVHLIDHF
CAGWGILIAAILELVGIIWIYGGNRFIEDTEMMIGAKRWIFWLWWRACWFVITPILLIAI
FIWSLVQFHRPNYGAIPYPDWGVALGWCMIVFCIIWIPIMAIIKIIQAKGNIFQRLISCC
RPASNWGPYLEQHRGERYKDMVDPKKEADHEIPTVSGSRKPE

# Drug_Target_20_Reaction:
Not Available

# Drug_Target_20_Signals:
None

# Drug_Target_20_Specific_Function:
Mediates the uptake of a broad range of neutral and cationic amino acids (with the exception of proline) in a (Na+/Cl-)-dependent manner

# Drug_Target_20_SwissProt_ID:
Q9UN76

# Drug_Target_20_SwissProt_Name:
S6A14_HUMAN

# Drug_Target_20_Synonyms:
0+
Amino acid transporter ATB0+
Solute carrier family 6 member 14

# Drug_Target_20_Theoretical_pI:
8.27

# Drug_Target_20_Transmembrane_Regions:
45-65
72-92
110-130
235-255
261-281
315-335
348-368
399-419
450-477
480-500
528-548
563-583

# Drug_Target_21_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_21_Chromosome_Location:
Not Available

# Drug_Target_21_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_21_Essentiality:
Non-Essential

# Drug_Target_21_GenAtlas_ID:
SLC6A7

# Drug_Target_21_GenBank_ID_Gene:
S80071

# Drug_Target_21_GenBank_ID_Protein:
8176779

# Drug_Target_21_GeneCard_ID:
SLC6A7

# Drug_Target_21_Gene_Name:
SLC6A7

# Drug_Target_21_Gene_Sequence:
>1911 bp
ATGAAGAAGCTCCAGGGAGCTCACCTCCGCAAGCCTGTCACCCCAGACCTGCTGATGACC
CCCAGTGACCAGGGCGATGTCGACCTGGATGTGGACTTTGCTGCACACCGGGGGAACTGG
ACAGGCAAGCTGGACTTCCTGCTGTCCTGCATTGGCTACTGTGTAGGCCTGGGGAATGTC
TGGCGCTTCCCCTATCGAGCGTACACCAATGGAGGAGGCGCCTTCCTCGTGCCCTACTTC
CTCATGCTGGCCATCTGTGGCATCCCCCTCTTCTTCCTGGAGCTCTCCCTGGGCCAGTTC
TCCAGCCTAGGGCCCCTGGCTGTCTGGAAAATCAGCCCTCTCTTCAAAGGCGCCGGCGCA
GCCATGCTGCTCATCGTGGGCTTGGTGGCCATCTACTACAACATGATCATCGCCTACGTG
CTCTTCTACCTCTTCGCCTCCCTCACCAGCGACCTACCCTGGGAGCACTGTGGCAACTGG
TGGAACACAGAACTCTGCCTGGAGCACAGAGTCTCCAAGGACGGCAACGGGGCCCTGCCC
CTCAACCTCACCTGCACCGTCAGCCCCAGTGAGGAGTACTGGAGCCGCTACGTCCTCCAC
ATCCAAGGCAGCCAGGGCATCGGCAGCCCTGGGGAGATCCGCTGGAACCTCTGCCTCTGC
CTGCTGCTGGCCTGGGTCATCGTGTTCCTCTGTATCCTCAAGGGTGTGAAGTCTTCGGGC
AAGGTGGTGTATTTCACGGCCACGTTCCCCTACCTCATCCTGCTCATGCTGCTGGTCCGC
GGAGTCACCCTCCCAGGGGCCTGGAAGGGCATCCAGTTCTATCTCACCCCCCAGTTCCAC
CACTTGTTGTCTTCCAAGGTGTGGATTGAAGCTGCTCTTCAGATCTTCTATTCCCTGGGT
GTGGGCTTCGGGGGGCTCCTCACCTTTGCCTCCTACAACACGTTTCACCAGAACATCTAT
AGAGACACCTTCATCGTCACTCTGGGCAACGCCATCACCAGCATCCTGGCTGGCTTTGCC
ATCTTCTCCGTGCTGGGCTACATGTCTCAGGAGCTGGGCGTGCCTGTGGACCAAGTAGCC
AAAGCAGGCCCTGGCCTGGCCTTTGTCGTCTACCCACAGGCCATGACCATGCTGCCTCTG
TCACCCTTCTGGTCCTTTCTCTTCTTCTTCATGCTTCTGACTCTCGGCCTAGATAGCCAG
TTTGCCTTTCTGGAGACCATTGTGACAGCTGTGACAGATGAGTTCCCATACTACCTGCGG
CCCAAGAAGGCGGTGTTCTCAGGGCTCATCTGCGTGGCCATGTACCTGATGGGGCTGATC
CTCACCACTGATGGGGGCATGTACTGGCTGGTCCTTCTGGATGACTACAGCGCCAGCTTC
GGGCTGATGGTGGTGGTTATCACCACATGCCTTGCCGTGACACGGGTGTATGGCATTCAG
AGGTTCTGCCGAGACATCCACATGATGCTGGGCTTCAAGCCGGGCCTCTACTTCAGGGCC
TGCTGGCTGTTCCTGTCCCCAGCCACGCTCTTGGCCCTCCTGGTGTATAGCATCGTCAAG
TACCAGCCCTCGGAGTATGGCAGTTACCGCTTCCCGCCCTGGGCTGAGCTGCTGGGCATC
CTGATGGGCCTGCTGTCCTGCCTCATGATCCCAGCTGGCATGCTGGTGGCTGTGCTTCGA
GAAGAGGGCTCACTCTGGGAGCGGCTCCAACAGGCCAGCCGGCCGGCCATGGACTGGGGA
CCATCGCTGGAGGAGAACCGGACGGGCATGTATGTGGCCACGCTGGCTGGGAGCCAGTCA
CCAAAGCCACTGATGGTGCACATGCGCAAGTACGGGGGCATCACCAGCTTCGAGAACACG
GCCATCGAGGTGGACCGTGAGATTGCAGAGGAGGAGGAGTCGATGATGTGA

# Drug_Target_21_General_Function:
Involved in neurotransmitter:sodium symporter activity

# Drug_Target_21_General_References:
7651355	Shafqat S, Velaz-Faircloth M, Henzi VA, Whitney KD, Yang-Feng TL, Seldin MF, Fremeau RT Jr: Human brain-specific L-proline transporter: molecular cloning, functional expression, and chromosomal localization of the gene in human and mouse genomes. Mol Pharmacol. 1995 Aug;48(2):219-29.

# Drug_Target_21_HGNC_ID:
HGNC:11054

# Drug_Target_21_HPRD_ID:
09371

# Drug_Target_21_ID:
797

# Drug_Target_21_Locus:
5q31-q32

# Drug_Target_21_Molecular_Weight:
70893

# Drug_Target_21_Name:
Sodium-dependent proline transporter

# Drug_Target_21_Number_of_Residues:
636

# Drug_Target_21_PDB_ID:
Not Available

# Drug_Target_21_Pathway:
Not Available

# Drug_Target_21_Pfam_Domain_Function:
PF00209	SNF

# Drug_Target_21_Protein_Sequence:
>Sodium-dependent proline transporter
MKKLQGAHLRKPVTPDLLMTPSDQGDVDLDVDFAAHRGNWTGKLDFLLSCIGYCVGLGNV
WRFPYRAYTNGGGAFLVPYFLMLAICGIPLFFLELSLGQFSSLGPLAVWKISPLFKGAGA
AMLLIVGLVAIYYNMIIAYVLFYLFASLTSDLPWEHCGNWWNTELCLEHRVSKDGNGALP
LNLTCTVSPSEEYWSRYVLHIQGSQGIGSPGEIRWNLCLCLLLAWVIVFLCILKGVKSSG
KVVYFTATFPYLILLMLLVRGVTLPGAWKGIQFYLTPQFHHLLSSKVWIEAALQIFYSLG
VGFGGLLTFASYNTFHQNIYRDTFIVTLGNAITSILAGFAIFSVLGYMSQELGVPVDQVA
KAGPGLAFVVYPQAMTMLPLSPFWSFLFFFMLLTLGLDSQFAFLETIVTAVTDEFPYYLR
PKKAVFSGLICVAMYLMGLILTTDGGMYWLVLLDDYSASFGLMVVVITTCLAVTRVYGIQ
RFCRDIHMMLGFKPGLYFRACWLFLSPATLLALLVYSIVKYQPSEYGSYRFPPWAELLGI
LMGLLSCLMIPAGMLVAVLREEGSLWERLQQASRPAMDWGPSLEENRTGMYVATLAGSQS
PKPLMVHMRKYGGITSFENTAIEVDREIAEEEESMM

# Drug_Target_21_Reaction:
Not Available

# Drug_Target_21_Signals:
None

# Drug_Target_21_Specific_Function:
Terminates the action of proline by its high affinity sodium-dependent reuptake into presynaptic terminals

# Drug_Target_21_SwissProt_ID:
Q99884

# Drug_Target_21_SwissProt_Name:
SC6A7_HUMAN

# Drug_Target_21_Synonyms:
Solute carrier family 6 member 7

# Drug_Target_21_Theoretical_pI:
6.66

# Drug_Target_21_Transmembrane_Regions:
46-66
74-93
117-137
215-233
242-259
295-312
324-345
378-397
425-443
459-479
500-519
538-556

# Drug_Target_22_Cellular_Location:
Not Available

# Drug_Target_22_Chromosome_Location:
Not Available

# Drug_Target_22_Drug_References:
11479381	Murahama M, Yoshida T, Hayashi F, Ichino T, Sanada Y, Wada K: Purification and characterization of Delta(1)-pyrroline-5-carboxylate reductase isoenzymes, indicating differential distribution in spinach (Spinacia oleracea L.) leaves. Plant Cell Physiol. 2001 Jul;42(7):742-50.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_22_Essentiality:
Non-Essential

# Drug_Target_22_GenAtlas_ID:
PYCR2

# Drug_Target_22_GenBank_ID_Gene:
AF087859

# Drug_Target_22_GenBank_ID_Protein:
33150582

# Drug_Target_22_GeneCard_ID:
PYCR2

# Drug_Target_22_Gene_Name:
PYCR2

# Drug_Target_22_Gene_Sequence:
>963 bp
ATGAGCGTGGGCTTCATCGGGGCCGGCCAGCTGGCTAATGCTCTGGCGCGGGGCTTCACG
GCCGCAGCATTCCTGTCGGCTCACAAGATAATAGCCAGCTCCCCAGAAATGAACCTGCCC
ACGGTGTCCGCGCTCAGGAAGATGGGTGTGAACCTGACACGCAGCAACAAGGAGACGGTG
AAGCACAGCGACGTCCTGTTTCTGGCTGTGAAGCACATTATCATCCCCTTCATCCTGGAT
GAGATTGGGGCCGACGTGCAAGCCAGACACATCGTGGTCTCCTGTGCGGCTGGTGTCACC
ATCAGCTCTGTGGAGAAGAAGCTGATGGCATTCCAGCCAGCCCCCAAAGTGATTCGCTGC
ATGACCAACACACCTGTGGTAGTGCAGGAAGGCGCTACAGTGTACGCCACGGGCACCCAT
GCCCTGGTGGAGGATGGGCAGCTCCTGGAGCAGCTCATGAGCAGCGTGGGCTTCTGCACT
GAGGTGGAAGAGGACCTCATCGATGCCGTCACGGGGCTCAGTGGCAGCGGGCCTGCCTAT
GCATTCATGGCTCTGGACGCATTGGCTGATGGTGGGGTGAAGATGGGTTTGCCACGGCGC
CTGGCAATCCAACTCGGGGCCCAGGCTTTGCTGGGAGCTGCCAAGATGCTGCTGGACTCG
GAGCAGCATCCATGCCAGCTTAAGGACAATGTCTGCTCCCCTGGGGGAGCCACCATCCAC
GCCCTGCACTTTCTAGAGAGTGGGGGCTTCCGCTCTCTGCTCATCAATGCAGTTGAGGCC
TCCTGTATCCGAACACGAGAGCTACAGTCCATGGCCGACCAAGAAAAGATCTCCCCAGCT
GCCCTTAAGAAGACCCTCTTAGACAGAGTGAAGCTGGAATCCCCCACAGTCTCCACACTG
ACCCCCTCCAGCCCAGGGAAGCTCCTCACAAGAAGCCTGGCCCTGGGAGGCAAGAAGGAC
TAA

# Drug_Target_22_General_Function:
Amino acid transport and metabolism

# Drug_Target_22_General_References:
Not Available

# Drug_Target_22_HGNC_ID:
HGNC:30262

# Drug_Target_22_HPRD_ID:
17939

# Drug_Target_22_ID:
802

# Drug_Target_22_Locus:
1q42.12

# Drug_Target_22_Molecular_Weight:
33638

# Drug_Target_22_Name:
Pyrroline-5-carboxylate reductase 2

# Drug_Target_22_Number_of_Residues:
320

# Drug_Target_22_PDB_ID:
Not Available

# Drug_Target_22_Pathway:
Not Available

# Drug_Target_22_Pfam_Domain_Function:
PF03807	F420_oxidored

# Drug_Target_22_Protein_Sequence:
>Pyrroline-5-carboxylate reductase 2
MSVGFIGAGQLAYALARGFTAAGILSAHKIIASSPEMNLPTVSALRKMGVNLTRSNKETV
KHSDVLFLAVKPHIIPFILDEIGADVQARHIVVSCAAGVTISSVEKKLMAFQPAPKVIRC
MTNTPVVVQEGATVYATGTHALVEDGQLLEQLMSSVGFCTEVEEDLIDAVTGLSGSGPAY
AFMALDALADGGVKMGLPRRLAIQLGAQALLGAAKMLLDSEQHPCQLKDNVCSPGGATIH
ALHFLESGGFRSLLINAVEASCIRTRELQSMADQEKISPAALKKTLLDRVKLESPTVSTL
TPSSPGKLLTRSLALGGKKD

# Drug_Target_22_Reaction:
L-proline + NAD(P)+ = 1-pyrroline-5-carboxylate + NAD(P)H + H+

# Drug_Target_22_Signals:
None

# Drug_Target_22_Specific_Function:
Not Available

# Drug_Target_22_SwissProt_ID:
Q96C36

# Drug_Target_22_SwissProt_Name:
P5CR2_HUMAN

# Drug_Target_22_Synonyms:
EC 1.5.1.2
P5C reductase 2
P5CR 2

# Drug_Target_22_Theoretical_pI:
7.87

# Drug_Target_22_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Mitochondrion

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
16511143	White TA, Tanner JJ: Cloning, purification and crystallization of Thermus thermophilus proline dehydrogenase. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Aug 1;61(Pt 8):737-9. Epub 2005 Jul 8.
17344208	White TA, Krishnan N, Becker DF, Tanner JJ: Structure and kinetics of monofunctional proline dehydrogenase from Thermus thermophilus. J Biol Chem. 2007 May 11;282(19):14316-27. Epub 2007 Mar 7.
17536821	Huang TC, Huang YW, Hung HJ, Ho CT, Wu ML: Delta1-pyrroline-5-carboxylic acid formed by proline dehydrogenase from the Bacillus subtilis ssp. natto expressed in Escherichia coli as a precursor for 2-acetyl-1-pyrroline. J Agric Food Chem. 2007 Jun 27;55(13):5097-102. Epub 2007 May 31.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
PRODH

# Drug_Target_2_GenBank_ID_Gene:
U82381

# Drug_Target_2_GenBank_ID_Protein:
2677802

# Drug_Target_2_GeneCard_ID:
PRODH

# Drug_Target_2_Gene_Name:
PRODH

# Drug_Target_2_Gene_Sequence:
>1551 bp
ATGCTGGAATTTGTGATGAGAGAGTGGAAAAAATCCAGGAAACTTCTAGGACAGAGGCTA
TTCAACAAGCTCATGAAGATGACCTTCTATGGGCATTTTGTAGCCGGGGAGGACCAGGAG
TCCATCCAGCCCCTGCTTCGGCACTACAGGGCCTTCGGTGTCAGCGCCATCCTGGACTAT
GGAGTGGAGGAGGACCTGAGCCCCGAGGAGGCAGAGCACAAGGAGATGGAGTCCTGCTCC
TCGGCTGCGGAGAGGGATGGCAGTGGCACGAATAAGCGGGACAAGCAATACCAGGCCCAC
CGGGCTTTCGGGGACCGCAGGAATGGTGTCATCAGTGCCCGCACCTACTTCTACGCCAAT
GAGGCCAAGTGCGACAGCCACATGGAGACATTCTTGCGCTGCATCGAAGCCTCAGGTAGA
GTCAGCGATGACGGCTTCATAGCCATTAAGCTCACAGCACTGGGGAGACCCCAGTTTCTG
CTGCAGTTCTCAGAGGTGCTGGCCAAGTGGAGGTGCTTCTTTCACCAAATGGCTGTGGAG
CAAGGGCAGGCGGGCCTGGCTGCCATGGACACCAAGCTGGAGGTGGCGGTGCTGCAGGAA
AGTGTCGCAAAGTTGGGCATCGCATCCAGGGCTGAGATTGAGGACTGGTTCACGGCAGAG
ACCCTGGGAGTGTCTGGCACCATGGACCTGCTGGACTGGAGCAGCCTCATCGACAGCAGG
ACCAAGCTGTCCAAGCACCTGGTAGTCCCCAACGCACAGACAGGACAGCTGGAGCCCCTG
CTGTCCCGGTTCACTGAGGAGGAGGAGCTACAGATGACCAGGATGCTACAGCGGATGGAT
GTCCTGGCCAAGAAAGCCACAGAGATGGGCGTGCGGCTGATGGTGGATGCCGAGCAGACC
TACTTCCAGCCGGCCATCAGCCGCCTGACGCTGGAGATGCAGCGGAAGTTCAATGTGGAG
AAGCCGCTCATCTTCAACACATACCAGTGCTACCTCAAGGATGCCTATGACAATGTGACC
CTGGACGTGGAGCTGGCTCGCCGTGAGGGCTGGTGTTTTGGGGCCAAGCTGGTGCGGGGC
GCATACCTGGCCCAGGAGCGAGCCCGTGCGGCAGAGATCGGCTATGAGGACCCCATCAAC
CCCACGTACGAGGCCACCAACGCCATGTACCACAGGTGCCTGGACTACGTGTTGGAGGAG
CTGAAGCACAACGCCAAGGCCAAGGTGATGGTGGCCTCCCACAATGAGGACACAGTGCGC
TTCGCACTGCGCAGGATGGAGGAGCTGGGCCTGCATCCTGCTGACCACCAGGTGTACTTT
GGACAGCTGCTAGGCATGTGTGACCAGATCAGCTTCCCGCTGGGCCAGGCCGGCTACCCC
GTGTACAAGTACGTGCCCTATGGCCCCGTGATGGAGGTGCTGCCCTACTTGTCCCGCCGT
GCCCTGGAGAACAGCAGCCTCATGAAGGGCACCCATCGGGAGCGGCAGTTGCTGTGGCTG
GAGCTCTTGAGGCGGCTCCGAACTGGCAACCTCTTCCATCGCCCTGCCTAG

# Drug_Target_2_General_Function:
Amino acid transport and metabolism

# Drug_Target_2_General_References:
10192398	Gogos JA, Santha M, Takacs Z, Beck KD, Luine V, Lucas LR, Nadler JV, Karayiorgou M: The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nat Genet. 1999 Apr;21(4):434-9.
9305847	Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B: A model for p53-induced apoptosis. Nature. 1997 Sep 18;389(6648):300-5.
9385373	Campbell HD, Webb GC, Young IG: A human homologue of the Drosophila melanogaster sluggish-A (proline oxidase) gene maps to 22q11.2, and is a candidate gene for type-I hyperprolinaemia. Hum Genet. 1997 Nov;101(1):69-74.

# Drug_Target_2_HGNC_ID:
HGNC:9453

# Drug_Target_2_HPRD_ID:
08433

# Drug_Target_2_ID:
4082

# Drug_Target_2_Locus:
22q11.21

# Drug_Target_2_Molecular_Weight:
59232

# Drug_Target_2_Name:
Proline oxidase, mitochondrial

# Drug_Target_2_Number_of_Residues:
516

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01619	Pro_dh

# Drug_Target_2_Protein_Sequence:
>Proline oxidase, mitochondrial
MLEFVMREWKKSRKLLGQRLFNKLMKMTFYGHFVAGEDQESIQPLLRHYRAFGVSAILDY
GVEEDLSPEEAEHKEMESCTSAAERDGSGTNKRDKQYQAHRAFGDRRNGVISARTYFYAN
EAKCDSHMETFLRCIEASGRVSDDGFIAIKLTALGRPQFLLQFSEVLAKWRCFFHQMAVE
QGQAGLAAMDTKLEVAVLQESVAKLGIASRAEIEDWFTAETLGVSGTMDLLDWSSLIDSR
TKLSKHLVVPNAQTGQLEPLLSRFTEEEELQMTRMLQRMDVLAKKATEMGVRLMVDAEQT
YFQPAISRLTLEMQRKFNVEKPLIFNTYQCYLKDAYDNVTLDVELARREGWCFGAKLVRG
AYLAQERARAAEIGYEDPINPTYEATNAMYHRCLDYVLEELKHNAKAKVMVASHNEDTVR
FALRRMEELGLHPADHQVYFGQLLGMCDQISFPLGQAGYPVYKYVPYGPVMEVLPYLSRR
ALENSSLMKGTHRERQLLWLELLRRLRTGNLFHRPA

# Drug_Target_2_Reaction:
L-proline + acceptor = (S)-1-pyrroline-5-carboxylate + reduced acceptor

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Converts proline to delta-1-pyrroline-5-carboxylate

# Drug_Target_2_SwissProt_ID:
O43272

# Drug_Target_2_SwissProt_Name:
PROD_HUMAN

# Drug_Target_2_Synonyms:
EC 1.5.99.8
P53-induced gene 6 protein
Proline dehydrogenase
Proline oxidase 2
Proline oxidase, mitochondrial precursor

# Drug_Target_2_Theoretical_pI:
6.88

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Nucleus

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
PPIH

# Drug_Target_3_GenBank_ID_Gene:
AF016371

# Drug_Target_3_GenBank_ID_Protein:
2708309

# Drug_Target_3_GeneCard_ID:
PPIH

# Drug_Target_3_Gene_Name:
PPIH

# Drug_Target_3_Gene_Sequence:
>534 bp
ATGGCGGTGGCAAATTCAAGTCCTGTTAACCCCGTGGTGTTCTTTGATGTCAGTATTGGC
GGTCAGGAAGTTGGCCGCATGAAGATCGAGCTCTTTGCAGACGTTGTGCCTAAGACGGCC
GAGAACTTTAGGCAGTTCTGCACCGGAGAATTCAGGAAAGATGGGGTTCCAATAGGATAC
AAAGGAAGCACCTTCCACAGGGTCATAAAGGATTTCATGATTCAGGGTGGAGATTTTGTT
AATGGAGATGGTACTGGAGTCGCCAGTATTTACCGGGGGCCATTTGCAGATGAAAATTTT
AAACTTAGACACTCAGCTCCAGGCCTGCTTTCCATGGCGAACAGTGGTCCAAGTACAAAT
GGCTGTCAGTTCTTTATCACCTGCTCTAAGTGCGATTGGCTGGATGGGAAGCATGTGGTG
TTTGGAAAAATCATCGATGGACTTCTAGTGATGAGAAAGATTGAGAATGTTCCCACAGGC
CCCAACAATAAGCCCAAGCTACCTGTGGTGATCTCGCAGTGTGGGGAGATGTAG

# Drug_Target_3_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_3_General_References:
10713041	Reidt U, Reuter K, Achsel T, Ingelfinger D, Luhrmann R, Ficner R: Crystal structure of the human U4/U6 small nuclear ribonucleoprotein particle-specific SnuCyp-20, a nuclear cyclophilin. J Biol Chem. 2000 Mar 17;275(11):7439-42.
11823439	Horowitz DS, Lee EJ, Mabon SA, Misteli T: A cyclophilin functions in pre-mRNA splicing. EMBO J. 2002 Feb 1;21(3):470-80.
12875835	Reidt U, Wahl MC, Fasshauer D, Horowitz DS, Luhrmann R, Ficner R: Crystal structure of a complex between human spliceosomal cyclophilin H and a U4/U6 snRNP-60K peptide. J Mol Biol. 2003 Aug 1;331(1):45-56.
9404889	Horowitz DS, Kobayashi R, Krainer AR: A new cyclophilin and the human homologues of yeast Prp3 and Prp4 form a complex associated with U4/U6 snRNPs. RNA. 1997 Dec;3(12):1374-87.
9570313	Teigelkamp S, Achsel T, Mundt C, Gothel SF, Cronshagen U, Lane WS, Marahiel M, Luhrmann R: The 20kD protein of human [U4/U6.U5] tri-snRNPs is a novel cyclophilin that forms a complex with the U4/U6-specific 60kD and 90kD proteins. RNA. 1998 Feb;4(2):127-41.

# Drug_Target_3_HGNC_ID:
HGNC:14651

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
4083

# Drug_Target_3_Locus:
1p34.1

# Drug_Target_3_Molecular_Weight:
19208

# Drug_Target_3_Name:
Peptidyl-prolyl cis-trans isomerase H

# Drug_Target_3_Number_of_Residues:
177

# Drug_Target_3_PDB_ID:
1MZW

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00160	Pro_isomerase

# Drug_Target_3_Protein_Sequence:
>Peptidyl-prolyl cis-trans isomerase H
MAVANSSPVNPVVFFDVSIGGQEVGRMKIELFADVVPKTAENFRQFCTGEFRKDGVPIGY
KGSTFHRVIKDFMIQGGDFVNGDGTGVASIYRGPFADENFKLRHSAPGLLSMANSGPSTN
GCQFFITCSKCDWLDGKHVVFGKIIDGLLVMRKIENVPTGPNNKPKLPVVISQCGEM

# Drug_Target_3_Reaction:
peptidylproline (omega=180) = peptidylproline (omega=0)

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Participates in pre-mRNA splicing. May play a role in the assembly of the U4/U5/U6 tri-snRNP complex. May act as a chaperone

# Drug_Target_3_SwissProt_ID:
O43447

# Drug_Target_3_SwissProt_Name:
PPIH_HUMAN

# Drug_Target_3_Synonyms:
CypH
EC 5.2.1.8
PPIase H
Rotamase H
Small nuclear ribonucleoprotein particle-specific cyclophilin H
U-snRNP-associated cyclophilin SnuCyp-20
USA-CYP

# Drug_Target_3_Theoretical_pI:
8.22

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Not Available

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
PROSC

# Drug_Target_4_GenBank_ID_Gene:
AB018566

# Drug_Target_4_GenBank_ID_Protein:
4126978

# Drug_Target_4_GeneCard_ID:
PROSC

# Drug_Target_4_Gene_Name:
PROSC

# Drug_Target_4_Gene_Sequence:
>828 bp
ATGTGGAGAGCTGGCAGCATGTCGGCCGAGCTGGGAGTCGGGTGCGCATTGCGGGCGGTG
AACGAGCGCGTGCAGCAGGCTGTGGCGCGGCGGCCGCGGGATCTCCCAGCCATCCAGCCC
CGGCTAGTGGCGGTCAGCAAAACCAAACCTGCAGACATGGTGATCGAGGCCTATGGACAT
GGGCAGCGCACTTTTGGCGAGAACTACGTTCAGGAACTGCTAGAAAAAGCATCAAATCCC
AAAATTCTGTCTTTGTGTCCTGAGATCAAATGGCACTTCATTGGCCACCTACAGAAACAA
AATGTCAACAAATTGATGGCTGTCCCCAATCTCTTCATGCTGGAAACAGTGGATTCTGTG
AAGTTGGCAGACAAAGTGAACAGTTCCTGGCAGAGAAAAGGTTCTCCTGAAAGGTTAAAG
GTTATGGTCCAGATTAACACCAGCGGAGAAGAGAGTAAACATGGCCTTCCACCTTCAGAG
ACCATAGCCATCGTGGAGCACATAAACGCCAAGTGTCCTAACCTGGAGTTTGTGGGGCTG
ATGACCATAGGAAGCTTTGGGCATGATCTTAGTCAAGGACCAAATCCAGACTTCCAGCTG
TTATTGTCCCTCCGGGAGGAGCTGTGTAAAAAGCTGAACATCCCTGCTGACCAGGTTGAG
CTGAGCATGGGCATGTCCGCGGATTTCCAGCATGCGGTTGAAGTAGGATCTACAAATGTC
CGAATAGGAAGCACGATTTTTGGAGAGCGGGATTACTCAAAGAAACCCACCCCGGACAAG
TGCGCAGCAGACGTGAAGGCCCCGCTGGAGGTGGCACAGGAGCACTGA

# Drug_Target_4_General_Function:
Not Available

# Drug_Target_4_General_References:
10496079	Ikegawa S, Isomura M, Koshizuka Y, Nakamura Y: Cloning and characterization of human and mouse PROSC (proline synthetase co-transcribed) genes. J Hum Genet. 1999;44(5):337-42.
11230166	Wiemann S, Weil B, Wellenreuther R, Gassenhuber J, Glassl S, Ansorge W, Bocher M, Blocker H, Bauersachs S, Blum H, Lauber J, Dusterhoft A, Beyer A, Kohrer K, Strack N, Mewes HW, Ottenwalder B, Obermaier B, Tampe J, Heubner D, Wambutt R, Korn B, Klein M, Poustka A: Toward a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs. Genome Res. 2001 Mar;11(3):422-35.

# Drug_Target_4_HGNC_ID:
HGNC:9457

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
3874

# Drug_Target_4_Locus:
8p11.2

# Drug_Target_4_Molecular_Weight:
30344

# Drug_Target_4_Name:
Proline synthetase co-transcribed bacterial homolog protein

# Drug_Target_4_Number_of_Residues:
275

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF01168	Ala_racemase_N

# Drug_Target_4_Protein_Sequence:
>Proline synthetase co-transcribed bacterial homolog protein
MWRAGSMSAELGVGCALRAVNERVQQAVARRPRDLPAIQPRLVAVSKTKPADMVIEAYGH
GQRTFGENYVQELLEKASNPKILSLCPEIKWHFIGHLQKQNVNKLMAVPNLFMLETVDSV
KLADKVNSSWQRKGSPERLKVMVQINTSGEESKHGLPPSETIAIVEHINAKCPNLEFVGL
MTIGSFGHDLSQGPNPDFQLLLSLREELCKKLNIPADQVELSMGMSADFQHAVEVGSTNV
RIGSTIFGERDYSKKPTPDKCAADVKAPLEVAQEH

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Not Available

# Drug_Target_4_SwissProt_ID:
O94903

# Drug_Target_4_SwissProt_Name:
PROSC_HUMAN

# Drug_Target_4_Synonyms:
Not Available

# Drug_Target_4_Theoretical_pI:
7.57

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Endoplasmic reticulum
endoplasmic reticulum lumen

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
P4HA1

# Drug_Target_5_GenBank_ID_Gene:
M24486

# Drug_Target_5_GenBank_ID_Protein:
190786

# Drug_Target_5_GeneCard_ID:
P4HA1

# Drug_Target_5_Gene_Name:
P4HA1

# Drug_Target_5_Gene_Sequence:
>1605 bp
ATGATCTGGTATATATTAATTATAGGAATTCTGCTTCCCCAGTCTTTGGCTCATCCAGGC
TTTTTTACTTCAATTGGTCAGATGACTGATTTGATCCATACTGAGAAAGATCTGGTGACT
TCTCTGAAAGATTATATTAAGGCAGAAGAGGACAAGTTAGAACAAATAAAAAAATGGGCA
GAGAAGTTAGATCGGCTAACTAGTACAGCGACAAAAGATCCAGAAGGATTTGTTGGGCAT
CCAGTAAATGCATTCAAATTAATGAAACGTCTGAATACTGAGTGGAGTGAGTTGGAGAAT
CTGGTCCTTAAGGATATGTCAGATGGCTTTATCTCTAACCTAACCATTCAGAGACCAGTA
CTTTCTAATGATGAAGATCAGGTTGGGGCAGCCAAAGCTCTGTTACGTCTCCAGGATACC
TACAATTTGGATACAGATACCATCTCAAAGGGTAATCTTCCAGGAGTGAAACACAAATCT
TTTCTAACGGCTGAGGACTGCTTTGAGTTGGGCAAAGTGGCCTATACAGAAGCAGATTAT
TACCATACGGAACTGTGGATGGAACAAGCCCTAAGGCAACTGGATGAAGGCGAGATTTCT
ACCATAGATAAAGTCTCTGTTCTAGATTATTTGAGCTATGCGGTATATCAGCAGGGAGAC
CTGGATAAGGCACTTTTGCTCACAAAGAAGCTTCTTGAACTAGATCCTGAACATCAGAGA
GCTAATGGTAACTTAAAATATTTTGAGTATATAATGGCTAAAGAAAAAGATGTCAATAAG
TCTGCTTCAGATGACCAATCTGATCAGAAAACTACACCAAAGAAAAAAGGGGTTGCTGTG
GATTACCTGCCAGAGAGACAGAAGTACGAAATGCTGTGCCGTGGGGAGGGTATCAAAATG
ACCCCTCGGAGACAGAAAAAACTCTTTTGCCGCTACCATGATGGAAACCGTAATCCTAAA
TTTATTCTGGCTCCAGCTAAACAGGAGGATGAATGGGACAAGCCTCGTATTATTCGCTTC
CATGATATTATTTCTGATGCAGAAATTGAAATCGTCAAAGACCTAGCAAAACCAAGGCTG
AGCCGAGCTACAGTACATGACCCTGAGACTGGAAAATTGACCACAGCACAGTACAGAGTA
TCTAAGAGTGCCTGGCTCTCTGGCTATGAAAATCCTGTGGTGTCTCGAATTAATATGAGA
ATACAAGATCTAACAGGACTAGATGTTTCCACAGCAGAGGAATTACAGGTAGCAAATTAT
GGAGTTGGAGGACAGTATGAACCCCATTTTGACTTTGCACGGAAAGATGAGCCAGATGCT
TTCAAAGAGCTGGGGACAGGAAATAGAATTGCTACATGGCTGTTTTATATGAGTGATGTG
TCTGCAGGAGGAGCCACTGTTTTTCCTGAAGTTGGAGCTAGTGTTTGGCCCAAAAAAGGA
ACTGCTGTTTTCTGGTATAATCTGTTTGCCAGTGGAGAAGGAGATTATAGTACACGGCAT
GCAGCCTGTCCAGTGCTAGTTGGCAACAAATGGGTATCCAATAAATGGCTCCATGAACGT
GGACAAGAATTTCGAAGACCTTGTACGTTGTCAGAATTGGAATGA

# Drug_Target_5_General_Function:
Involved in oxidoreductase activity

# Drug_Target_5_General_References:
2543975	Helaakoski T, Vuori K, Myllyla R, Kivirikko KI, Pihlajaniemi T: Molecular cloning of the alpha-subunit of human prolyl 4-hydroxylase: the complete cDNA-derived amino acid sequence and evidence for alternative splicing of RNA transcripts. Proc Natl Acad Sci U S A. 1989 Jun;86(12):4392-6.
7961714	Helaakoski T, Veijola J, Vuori K, Rehn M, Chow LT, Taillon-Miller P, Kivirikko KI, Pihlajaniemi T: Structure and expression of the human gene for the alpha subunit of prolyl 4-hydroxylase. The two alternatively spliced types of mRNA correspond to two homologous exons the sequences of which are expressed in a variety of tissues. J Biol Chem. 1994 Nov 11;269(45):27847-54.

# Drug_Target_5_HGNC_ID:
HGNC:8546

# Drug_Target_5_HPRD_ID:
08901

# Drug_Target_5_ID:
67

# Drug_Target_5_Locus:
10q21.3-q23.1

# Drug_Target_5_Molecular_Weight:
61050

# Drug_Target_5_Name:
Prolyl 4-hydroxylase subunit alpha-1

# Drug_Target_5_Number_of_Residues:
534

# Drug_Target_5_PDB_ID:
1TJC

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF03171	2OG-FeII_Oxy
PF07719	TPR_2
PF08336	P4Ha_N

# Drug_Target_5_Protein_Sequence:
>Prolyl 4-hydroxylase alpha-1 subunit precursor
MIWYILIIGILLPQSLAHPGFFTSIGQMTDLIHTEKDLVTSLKDYIKAEEDKLEQIKKWA
EKLDRLTSTATKDPEGFVGHPVNAFKLMKRLNTEWSELENLVLKDMSDGFISNLTIQRQY
FPNDEDQVGAAKALLRLQDTYNLDTDTISKGNLPGVKHKSFLTAEDCFELGKVAYTEADY
YHTELWMEQALRQLDEGEISTIDKVSVLDYLSYAVYQQGDLDKALLLTKKLLELDPEHQR
ANGNLKYFEYIMAKEKDVNKSASDDQSDQKTTPKKKGVAVDYLPERQKYEMLCRGEGIKM
TPRRQKKLFCRYHDGNRNPKFILAPAKQEDEWDKPRIIRFHDIISDAEIEIVKDLAKPRL
RRATISNPITGDLETVHYRISKSAWLSGYENPVVSRINMRIQDLTGLDVSTAEELQVANY
GVGGQYEPHFDFARKDEPDAFKELGTGNRIATWLFYMSDVSAGGATVFPEVGASVWPKKG
TAVFWYNLFASGEGDYSTRHAACPVLVGNKWVSNKWLHERGQEFRRPCTLSELE

# Drug_Target_5_Reaction:
procollagen L-proline + 2-oxoglutarate + O2 = procollagen trans-4-hydroxy-L-proline + succinate + CO2

# Drug_Target_5_Signals:
1-17

# Drug_Target_5_Specific_Function:
Catalyzes the posttranslational formation of 4- hydroxyproline in -Xaa-Pro-Gly- sequences in collagens and other proteins

# Drug_Target_5_SwissProt_ID:
P13674

# Drug_Target_5_SwissProt_Name:
P4HA1_HUMAN

# Drug_Target_5_Synonyms:
4-PH alpha-1
EC 1.14.11.2
Procollagen-proline,2-oxoglutarate-4-dioxygenase alpha-1 subunit
Prolyl 4-hydroxylase subunit alpha-1 precursor

# Drug_Target_5_Theoretical_pI:
5.84

# Drug_Target_5_Transmembrane_Regions:
None

# Drug_Target_6_Cellular_Location:
Endoplasmic reticulum

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
PPIB

# Drug_Target_6_GenBank_ID_Gene:
M60857

# Drug_Target_6_GenBank_ID_Protein:
181335

# Drug_Target_6_GeneCard_ID:
PPIB

# Drug_Target_6_Gene_Name:
PPIB

# Drug_Target_6_Gene_Sequence:
>627 bp
ATGAAGGTGCTCCTTGCCGCCGCCCTCATCGCGGGGTCCGTCTTCTTCCTGCTGCTGCCG
GGACCTTCTGCGGCCGATGAGAAGAAGAAGGGGCCCAAAGTCACCGTCAAGGTGTATTTT
GACCTACGAATTGGAGATGAAGATGTAGGCCGGGTGATCTTTGGTCTCTTCGGAAAGACT
GTTCCAAAAACAGTGGATAATTTTGTGGCCTTAGCTACAGGAGAGAAAGGATTTGGCTAC
AAAAACAGCAAATTCCATCGTGTAATCAAGGACTTCATGATCCAGGGCGGAGACTTCACC
AGGGGAGATGGCACAGGAGGAAAGAGCATCTACGGTGAGCGCTTCCCCGATGAGAACTTC
AAACTGAAGCACTACGGGCCTGGCTGGGTCAGCATGGCCAACGCAGGCAAAGACACCAAC
GGCTCCCAGTTCTTCATCACGACAGTCAAGACAGCCTGGCTAGATGGCAAGCATGTGGTG
TTTGGCAAAGTTCTAGAGGGCATGGAGGTGGTGCGGAAGGTGGAGAGCACCAAGACAGAC
AGCCGGGATAAACCCCTGAAGGATGTGATCATCGCAGACTGCGGCAAGATCGAGGTGGAG
AAGCCCTTTGCCATCGCCAAGGAGTAG

# Drug_Target_6_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_6_General_References:
1286667	Rasmussen HH, van Damme J, Puype M, Gesser B, Celis JE, Vandekerckhove J: Microsequences of 145 proteins recorded in the two-dimensional gel protein database of normal human epidermal keratinocytes. Electrophoresis. 1992 Dec;13(12):960-9.
1530944	Arber S, Krause KH, Caroni P: s-cyclophilin is retained intracellularly via a unique COOH-terminal sequence and colocalizes with the calcium storage protein calreticulin. J Cell Biol. 1992 Jan;116(1):113-25.
1710767	Hasel KW, Glass JR, Godbout M, Sutcliffe JG: An endoplasmic reticulum-specific cyclophilin. Mol Cell Biol. 1991 Jul;11(7):3484-91.
2000394	Price ER, Zydowsky LD, Jin MJ, Baker CH, McKeon FD, Walsh CT: Human cyclophilin B: a second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence. Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1903-7.
2040592	Spik G, Haendler B, Delmas O, Mariller C, Chamoux M, Maes P, Tartar A, Montreuil J, Stedman K, Kocher HP, et al.: A novel secreted cyclophilin-like protein (SCYLP). J Biol Chem. 1991 Jun 15;266(17):10735-8.
8197205	Mikol V, Kallen J, Walkinshaw MD: X-ray structure of a cyclophilin B/cyclosporin complex: comparison with cyclophilin A and delineation of its calcineurin-binding domain. Proc Natl Acad Sci U S A. 1994 May 24;91(11):5183-6.

# Drug_Target_6_HGNC_ID:
HGNC:9255

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
4084

# Drug_Target_6_Locus:
15q21-q22

# Drug_Target_6_Molecular_Weight:
22743

# Drug_Target_6_Name:
Peptidyl-prolyl cis-trans isomerase B

# Drug_Target_6_Number_of_Residues:
208

# Drug_Target_6_PDB_ID:
1CYN

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF00160	Pro_isomerase

# Drug_Target_6_Protein_Sequence:
>Peptidyl-prolyl cis-trans isomerase B
MKVLLAAALIAGSVFFLLLPGPSAADEKKKGPKVTVKVYFDLRIGDEDVGRVIFGLFGKT
VPKTVDNFVALATGEKGFGYKNSKFHRVIKDFMIQGGDFTRGDGTGGKSIYGERFPDENF
KLKHYGPGWVSMANAGKDTNGSQFFITTVKTAWLDGKHVVFGKVLEGMEVVRKVESTKTD
SRDKPLKDVIIADCGKIEVEKPFAIAKE

# Drug_Target_6_Reaction:
peptidylproline (omega=180) = peptidylproline (omega=0)

# Drug_Target_6_Signals:
1-25

# Drug_Target_6_Specific_Function:
PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides

# Drug_Target_6_SwissProt_ID:
P23284

# Drug_Target_6_SwissProt_Name:
PPIB_HUMAN

# Drug_Target_6_Synonyms:
CYP-S1
Cyclophilin B
EC 5.2.1.8
PPIase
Peptidyl-prolyl cis-trans isomerase B precursor
Rotamase
S-cyclophilin
SCYLP

# Drug_Target_6_Theoretical_pI:
9.97

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Mitochondrion
mitochondrial matrix

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
PPIF

# Drug_Target_7_GenBank_ID_Gene:
M80254

# Drug_Target_7_GenBank_ID_Protein:
181274

# Drug_Target_7_GeneCard_ID:
PPIF

# Drug_Target_7_Gene_Name:
PPIF

# Drug_Target_7_Gene_Sequence:
>624 bp
ATGCTGGCGCTGCGCTGCGGCTCCCGCTGGCTCGGCCTGCTCTCCGTCCCGCGCTCCGTG
CCGCTGCGCCTCCCCGCGGCCCGCGCCTGCAGCAAGGGCTCCGGCGACCCGTCCTCTTCC
TCCTCCTCCGGGAACCCGCTCGTGTACCTGGACGTGGACGCCAACGGGAAGCCGCTCGGC
CGCGTGGTGCTGGAGCTGAAGGCAGATGTCGTCCCAAAGACAGCTGAGAACTTCAGAGCC
CTGTGCACTGGTGAGAAGGGCTTCGGCTACAAAGGCTCCACCTTCCACAGGGTGATCCCT
TCCTTCATGTGCCAGGCGGGCGACTTCACCAACCACAATGGCACAGGCGGGAAGTCCATC
TACGGAAGCCGCTTTCCTGACGAGAACTTTACACTGAAGCACGTGGGGCCAGGTGTCCTG
TCCATGGCTAATGCTGGTCCTAACACCAACGGCTCCCAGTTCTTCATCTGCACCATAAAG
ACAGACTGGTTGGATGGCAAGCATGTTGTGTTCGGTCACGTCAAAGAGGGCATGGACGTC
GTGAAGAAAATAGAATCTTTCGGCTCTAAGAGTGGGAGGACATCCAAGAAGATTGTCATC
ACAGACTGTGGCCAGTTGAGCTAA

# Drug_Target_7_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_7_General_References:
1744118	Bergsma DJ, Eder C, Gross M, Kersten H, Sylvester D, Appelbaum E, Cusimano D, Livi GP, McLaughlin MM, Kasyan K, et al.: The cyclophilin multigene family of peptidyl-prolyl isomerases. Characterization of three separate human isoforms. J Biol Chem. 1991 Dec 5;266(34):23204-14.

# Drug_Target_7_HGNC_ID:
HGNC:9259

# Drug_Target_7_HPRD_ID:
06839

# Drug_Target_7_ID:
2554

# Drug_Target_7_Locus:
10q22-q23

# Drug_Target_7_Molecular_Weight:
22040

# Drug_Target_7_Name:
Peptidyl-prolyl cis-trans isomerase, mitochondrial

# Drug_Target_7_Number_of_Residues:
207

# Drug_Target_7_PDB_ID:
2BIU

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF00160	Pro_isomerase

# Drug_Target_7_Protein_Sequence:
>Peptidyl-prolyl cis-trans isomerase, mitochondrial precursor
MLALRCGSRWLGLLSVPRSVPLRLPAARACSKGSGDPSSSSSSGNPLVYLDVDANGKPLG
RVVLELKADVVPKTAENFRALCTGEKGFGYKGSTFHRVIPSFMCQAGDFTNHNGTGGKSI
YGSRFPDENFTLKHVGPGVLSMANAGPNTNGSQFFICTIKTDWLDGKHVVFGHVKEGMDV
VKKIESFGSKSGRTSKKIVITDCGQLS

# Drug_Target_7_Reaction:
peptidylproline (omega=180) = peptidylproline (omega=0)

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides

# Drug_Target_7_SwissProt_ID:
P30405

# Drug_Target_7_SwissProt_Name:
PPIF_HUMAN

# Drug_Target_7_Synonyms:
Cyclophilin F
EC 5.2.1.8
PPIase
Peptidyl-prolyl cis-trans isomerase, mitochondrial precursor
Rotamase

# Drug_Target_7_Theoretical_pI:
9.95

# Drug_Target_7_Transmembrane_Regions:
None

# Drug_Target_8_Cellular_Location:
Cytoplasm

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
PPIC

# Drug_Target_8_GenBank_ID_Gene:
S71018

# Drug_Target_8_GenBank_ID_Protein:
547304

# Drug_Target_8_GeneCard_ID:
PPIC

# Drug_Target_8_Gene_Name:
PPIC

# Drug_Target_8_Gene_Sequence:
>639 bp
ATGGGCCCGGGTCCTCGGCTGCTGCTACCTCTCGTGCTTTGCGTGGGGCTCGGCGCACTT
GTGTTTTCTTCGGGGGCCGAGGGCTTCCGCAAGCGAGGCCCCTCGGTGACGGCCAAGGTC
TTCTTTGATGTGAGGATTGGAGACAAAGATGTTGGCAGAATTGTGATTGGCCTCTTTGGA
AAAGTTGTGCCCAAGACAGTGGAAAATTTTGTTGCTCTAGCAACAGGAGAGAAAGGATAT
GGATATAAAGGAAGCAAGTTTCATCGTGTCATCAAGGATTTCATGATTCAAGGAGGTGAC
ATCACCACTGGAGATGGCACTGGGGGTGTGAGCATCTATGGTGAGACATTTCCAGATGAG
AACTTCAAGCTGAAGCACTATGGCATTGGGTGGGTCAGCATGGCCAACGCTGGGCCTGAC
ACCAATGGCTCTCAGTTCTTTATCACCTTGACCAAGCCCACCTGGTTGGACGGCAAACAT
GTGGTGTTTGGAAAAGTCATTGATGGGATGACAGTGGTGCACTCCATAGAGCTCCAAGCA
ACTGATGGGCATGACCGTCCACTCACCAACTGCTCGATCATCAACAGTGGCAAGATAGAC
GTGAAAACGCCTTTTGTGGTTGAGATCGCTGATTGGTGA

# Drug_Target_8_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_8_General_References:
8031755	Schneider H, Charara N, Schmitz R, Wehrli S, Mikol V, Zurini MG, Quesniaux VF, Movva NR: Human cyclophilin C: primary structure, tissue distribution, and determination of binding specificity for cyclosporins. Biochemistry. 1994 Jul 12;33(27):8218-24.

# Drug_Target_8_HGNC_ID:
HGNC:9256

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
4085

# Drug_Target_8_Locus:
5q23.2

# Drug_Target_8_Molecular_Weight:
22764

# Drug_Target_8_Name:
Peptidyl-prolyl cis-trans isomerase C

# Drug_Target_8_Number_of_Residues:
212

# Drug_Target_8_PDB_ID:
2RMC

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00160	Pro_isomerase

# Drug_Target_8_Protein_Sequence:
>Peptidyl-prolyl cis-trans isomerase C
MGPGPRLLLPLVLCVGLGALVFSSGAEGFRKRGPSVTAKVFFDVRIGDKDVGRIVIGLFG
KVVPKTVENFVALATGEKGYGYKGSKFHRVIKDFMIQGGDITTGDGTGGVSIYGETFPDE
NFKLKHYGIGWVSMANAGPDTNGSQFFITLTKPTWLDGKHVVFGKVIDGMTVVHSIELQA
TDGHDRPLTNCSIINSGKIDVKTPFVVEIADW

# Drug_Target_8_Reaction:
peptidylproline (omega=180) = peptidylproline (omega=0)

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides

# Drug_Target_8_SwissProt_ID:
P45877

# Drug_Target_8_SwissProt_Name:
PPIC_HUMAN

# Drug_Target_8_Synonyms:
Cyclophilin C
EC 5.2.1.8
PPIase
Rotamase

# Drug_Target_8_Theoretical_pI:
8.69

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Cytoplasm

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
PPIA

# Drug_Target_9_GenBank_ID_Gene:
Y00052

# Drug_Target_9_GenBank_ID_Protein:
30309

# Drug_Target_9_GeneCard_ID:
PPIA

# Drug_Target_9_Gene_Name:
PPIA

# Drug_Target_9_Gene_Sequence:
>498 bp
ATGGTCAACCCCACCGTGTTCTTCGACATTGCCGTCGACGGCGAGCCCTTGGGCCGCGTC
TCCTTTGAGCTGTTTGCAGACAAGGTCCCAAAGACAGCAGAAAATTTTCGTGCTCTGAGC
ACTGGAGAGAAAGGATTTGGTTATAAGGGTTCCTGCTTTCACAGAATTATTCCAGGGTTT
ATGTGTCAGGGTGGTGACTTCACACGCCATAATGGCACTGGTGGCAAGTCCATCTATGGG
GAGAAATTTGAAGATGAGAACTTCATCCTAAAGCATACGGGTCCTGGCATCTTGTCCATG
GCAAATGCTGGACCCAACACAAATGGTTCCCAGTTTTTCATCTGCACTGCCAAGACTGAG
TGGTTGGATGGCAAGCATGTGGTGTTTGGCAAAGTGAAAGAAGGCATGAATATTGTGGAG
GCCATGGAGCGCTTTGGGTCCAGGAATGGCAAGACCAGCAAGAAGATCACCATTGCTGAC
TGTGGACAACTCGAATAA

# Drug_Target_9_General_Function:
Posttranslational modification, protein turnover, chaperones

# Drug_Target_9_General_References:
12665801	Gevaert K, Goethals M, Martens L, Van Damme J, Staes A, Thomas GR, Vandekerckhove J: Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. Epub 2003 Mar 31.
1896075	Kallen J, Spitzfaden C, Zurini MG, Wider G, Widmer H, Wuthrich K, Walkinshaw MD: Structure of human cyclophilin and its binding site for cyclosporin A determined by X-ray crystallography and NMR spectroscopy. Nature. 1991 Sep 19;353(6341):276-9.
1946361	Ke HM, Zydowsky LD, Liu J, Walsh CT: Crystal structure of recombinant human T-cell cyclophilin A at 2.5 A resolution. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9483-7.
2001362	Liu J, Chen CM, Walsh CT: Human and Escherichia coli cyclophilins: sensitivity to inhibition by the immunosuppressant cyclosporin A correlates with a specific tryptophan residue. Biochemistry. 1991 Mar 5;30(9):2306-10.
2197089	Haendler B, Hofer E: Characterization of the human cyclophilin gene and of related processed pseudogenes. Eur J Biochem. 1990 Jul 5;190(3):477-82.
3297675	Haendler B, Hofer-Warbinek R, Hofer E: Complementary DNA for human T-cell cyclophilin. EMBO J. 1987 Apr;6(4):947-50.
7657784	Meier U, Beier-Hellwig K, Klug J, Linder D, Beier HM: Identification of cyclophilin A from human decidual and placental tissue in the first trimester of pregnancy. Hum Reprod. 1995 May;10(5):1305-10.
8263916	Mikol V, Kallen J, Pflugl G, Walkinshaw MD: X-ray structure of a monomeric cyclophilin A-cyclosporin A crystal complex at 2.1 A resolution. J Mol Biol. 1993 Dec 20;234(4):1119-30.
8421500	Theriault Y, Logan TM, Meadows R, Yu L, Olejniczak ET, Holzman TF, Simmer RL, Fesik SW: Solution structure of the cyclosporin A/cyclophilin complex by NMR. Nature. 1993 Jan 7;361(6407):88-91.
8421501	Pflugl G, Kallen J, Schirmer T, Jansonius JN, Zurini MG, Walkinshaw MD: X-ray structure of a decameric cyclophilin-cyclosporin crystal complex. Nature. 1993 Jan 7;361(6407):91-4.
8513493	Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP: Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell. 1993 Jun 18;73(6):1067-78.
8652511	Zhao Y, Ke H: Crystal structure implies that cyclophilin predominantly catalyzes the trans to cis isomerization. Biochemistry. 1996 Jun 11;35(23):7356-61.
9299338	Ottiger M, Zerbe O, Guntert P, Wuthrich K: The NMR solution conformation of unligated human cyclophilin A. J Mol Biol. 1997 Sep 12;272(1):64-81.
9385632	Vajdos FF, Yoo S, Houseweart M, Sundquist WI, Hill CP: Crystal structure of cyclophilin A complexed with a binding site peptide from the HIV-1 capsid protein. Protein Sci. 1997 Nov;6(11):2297-307.
9769216	Kallen J, Mikol V, Taylor P, Walkinshaw MD: X-ray structures and analysis of 11 cyclosporin derivatives complexed with cyclophilin A. J Mol Biol. 1998 Oct 23;283(2):435-49.

# Drug_Target_9_HGNC_ID:
HGNC:9253

# Drug_Target_9_HPRD_ID:
00457

# Drug_Target_9_ID:
1524

# Drug_Target_9_Locus:
7p13

# Drug_Target_9_Molecular_Weight:
18013

# Drug_Target_9_Name:
Peptidyl-prolyl cis-trans isomerase A

# Drug_Target_9_Number_of_Residues:
165

# Drug_Target_9_PDB_ID:
1CWM

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00160	Pro_isomerase

# Drug_Target_9_Protein_Sequence:
>Peptidyl-prolyl cis-trans isomerase A
MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGF
MCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTE
WLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE

# Drug_Target_9_Reaction:
peptidylproline (omega=180) = peptidylproline (omega=0)

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides

# Drug_Target_9_SwissProt_ID:
P62937

# Drug_Target_9_SwissProt_Name:
PPIA_HUMAN

# Drug_Target_9_Synonyms:
Cyclophilin A
Cyclosporin A-binding protein
EC 5.2.1.8
PPIase A
Rotamase A

# Drug_Target_9_Theoretical_pI:
7.97

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB00172
